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Abstract 
 
Neuroblastoma (NBL) is the most common type of cancer diagnosed in the first 
year of life. It is a complex and heterogeneous disease that arises from the 
developing sympathetic nervous system. Despite numerous advances and the 
well-demonstrated role of MYCN in the pathogenesis of neuroblastoma, the 
mechanisms underlying its oncogenic function are not entirely understood and 
there is evidence that its function is, in part, dependent on the tumour 
microenvironment (TME). New and improved therapeutic targets are urgently 
required for this often lethal tumour. Heparan sulfate proteoglycans (HSPG) 
play a critical role in the interactions between tumour cells and the TME and 
their activities are dependent on the sulfation pattern, that is controlled by 
sulfotransferases, which add sulfate groups to the repeating disaccharide units, 
and sulfatases (SULFs), which selectively remove 6-O-sulfates. In this work an 
analysis of the expression of these enzymes in human neuroblastoma revealed 
higher levels of SULF2 specifically when the MYCN oncogene was amplified. 
Loss of expression of SULF2 in MYCN-amplified (A) cell lines was associated 
with a marked decrease in survival and an increase in apoptosis. Evidence is 
presented that SULF2 is a direct downstream target of MYCN since over-
expression of MYCN in neuroblastoma cells increases SULF2 expression 
whereas a down regulation reduced SULF2 expression. Underlying the 
importance of SULF2 in neuroblastoma cell survival independently of MYCN, it 
is demonstrated that overexpression of SULF2 in MYCN-NA cells increases cell 
viability without increasing MYCN expression. Analysis of SULF2 protein 
expression in a large cohort of primary human neuroblastoma tumours also 
indicated a high level of expression in MYCN-A tumours and an almost 
complete absence of expression in MYCN-non A (NA) tumours. The data 
identify SULF2 as a new downstream target of MYCN and a key contributor to 
its oncogenic function in human neuroblastoma, which might have future 
implications for clinical therapies for high-risk NBL. 
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Chapter 1: Introduction and Research Objectives 
1.1 Childhood cancer 
Every year about 1,600 children in the UK and 8,500 in the United States are 
diagnosed with cancer under 15 years of age; accounting for just 0.5 % of the 
total cancer diagnoses in all ages. In Europe, approximately 1 in 500-600 
children develop a malignant disease before the age of fifteen [Parkin et al., 
1998] although rare paediatric cancers are, next to accidents, the second most 
common cause of childhood death in developed countries [Kaatsch, 2010; 
Basta et al., 2011]. Since the declaration of war on cancer by USA president 
Nixon in 1971, and despite some improvements, little has changed in standard 
cancer therapy, which still comprises surgery, chemotherapy and radiation. 
Paediatric tumours such as high-risk neuroblastoma still have very poor 
outcomes.  
The seminal paper The Hallmarks of Cancer by Hanahan and Weinberg 
[Hanahan and Weinberg, 2011] suggested that all cancers can be described by 
a few principles. They describe tumour progression via eight “hallmarks” in a 
process analogous to Darwinian evolution, in which genetic changes provide a 
growth advantage to cells that have become cancerous.  
Childhood cancer is very different from adult cancers in many ways. Adult 
cancers are mostly epithelial carcinomas, whereas paediatric cancers are 
principally haematological malignancies, tumours from the central nervous 
system (CNS), lymphomas and embryonal tumours (i.e., neuroblastomas, 
retinoblastomas, nephroblastomas, embryonal rhabdomyosarcomas and germ 
cell tumours. The aetiology of childhood cancers remains unclear. Adult 
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tumours result from a multistep process that develops over several years or 
even decades. Childhood tumours have a much shorter carcinogenic process 
and environmental factors such as lifestyle, that are so significant in adults, 
have a very small aetiology, given the short time available between oncogenic 
exposure and disease [Grimmer et al., 2006]. Only 10 % of childhood cancers 
have a clear genetic predisposition that can be inherited from a parent, or occur 
de novo in the gametocytes before fertilisation. Germ line mutations are very 
rare in children. Over the last few decades many efforts have been focused on 
finding somatic mutations in human cancer, with the aim of identifying precise 
treatments for specific mutations. However, DNA mutations amongst paediatric 
tumours, and especially in NBL, are sparse, emphasizing the challenge of 
identifying new therapeutic targets for these tumours. Interestingly, even when 
excluding patients with known genetic conditions, many childhood cancers are 
associated with congenital anomalies [Miller RW, 1969]. One only has to think 
of what can happen when twinning goes awry; the spectrum of anomalies and 
embryology is extensive and ranges from monozygotic twins to conjoined twins, 
malformed external parasitic twins, fetus-in-fetu, to “fetaform” teratomas and 
finally teratomas. The idea of cancer as a “devolutionary” state has been noted 
in the early last century by scientists like Theodore Boveri [Boveri T, 2008], who 
recognised that cancer cells are similar to those seen during early embryonic 
development. So, one may ask; is the problem of cancer looked at in the wrong 
way?  
In contrast to conventional explanations for cancer, the unifying theory of 
cancer by Davies and Lineweaver [Davies and Lineweaver, 2011] explains 
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cancer as an evolutionary throwback and atavistic state, in which cancer cells 
are under the control of ancient programs. The same genes that have been 
passed on from very early ancestry and are present during normal embryonic 
life as cells, differentiating into specific organs, are switched on in cancer. The 
earlier the embryonic stage, the more basic will be the genes guiding 
development. This theory seems to be appropriate for paediatric tumours, in 
which many genetic pathways controlling early development such as MYCN 
and Wnt are re-activated or, as in NBL, the tumour can undergo spontaneous 
regression and/or mature from a malignant to a benign state [Brodeur 2003; 
Beckwith and Perrin 1963; Ikeda et al. 1981; Haase et al. 1988].  
In 1889 the English surgeon Stephen Paget proposed in his theory of the “seed 
and soil” of cancer, that metastasis relies on the cross-talk between the cancer 
cells (“the seed”) and the specific organ microenvironment (“the soil”) [Paget, 
1889]. Numerous pieces of evidence illustrate the importance of the tumour 
microenvironment for tumour progression and therapeutic responses [Hanahan 
and Coussen, 2012; Whiteside 2008; Joyce and Pollard, 2009]. The 
microenvironment of the tumour can not only support the development of 
cancer, but also adversely impact the efficacy of clinical therapy [Quail and 
Joyce 2013; Hanahan and Coussen, 2012]. Anti-microenvironment therapy 
against blood vessels with the aim of starving the tumour was pioneered by the 
paediatric surgeon Judah Folkman [Folkman, 1971] and a drug was later 
approved by the US-FDA in 2004 for colorectal cancer and lung carcinoma, 
HER2 negative breast cancer and glioblastoma [Carmeliet and Jain, 2011; Jain 
et al., 2006; Ferrara 2009]. Clinical trials were encouraging but high efficacy 
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requires additional cytotoxic chemotherapy. A comprehensive understanding of 
the biological mechanism of the tumour microenvironment is required for 
successful therapeutic targeting [Valastyan and Weinberg, 2011]. Most studies 
are focused on the protein component, while other essential key regulators of 
the ECM, such as heparan sulfate proteoglycans (HSPGs), are largely 
neglected. Similar to other atavistic structures, heparan sulfate (HS) appeared 
in early metazoan life and is known to regulate the activity of many extracellular 
proteins and extracellular matrix components [Esko and Selleck, 2002; Häcker 
et al., 2005; Turnbull, 2007]. Recent evidence shows the role of HS in the 
tumour microenvironment [Sasiskeran et al., 2002; Iozzo 2005; Sanderson et 
al., 2005; Phillips et al., 2012]. Early evidence in the 1980’s showed that 
neuroblastoma has altered sulfation with an increase in 6O-sulfation [Hampson 
et al., 1983; Hampson et al., 1984]. Extensive reports in the literature showed 
that cellular transformation and behaviour in malignancy correlates with 
changes in HS expression and structure including 6O-sulfation [Jayson et al., 
1998; Delcommenne et al., 2012]. Similarly our preliminary data revealed that 
neuroblastoma cells and tissue have increased levels of HS and of 6O-sulfation 
by disaccharide analysis (see Appendix 1). Little is known about the host 
microenvironment of NBL. Studying the glycobiological aspect of this 
developmental tumour, in which the microenvironment and embryological 
genes, such as MYCN, play a critical role, could represent a novel molecular 
direction and a missing link.  
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1.2 Neuroblastoma 
1.2.1 Historical and general background 
“Mit einer gewissen Zaghaftigkeit erwähne ich hier noch einer 
geschwulstartigen Bildung, nähmlich partieller Hyperplasien der Marksubstanz 
der Nebennieren. Bekanntlichist von vielen neueren Beobachtern diese 
Substanz für eine wesentlich nervöse angesehen worden, [Virchow, 1865]; {“It 
is with a certain diffidence that I bring up here another tumour-like condition, 
namely partial hyperplasia of the marrow substance of the adrenal glands.”  }.. It 
is with these words that in 1864 just 5 years after Darwin’s “The Origin of 
Species”, the concept of neuroblastoma was introduced by the great pathologist 
Rudolf Virchow in his seminal work “Die Krankhaften Geschwülste” (“The 
morbid growths”). However, the first description of this enigmatic tumour was a 
misconception as the sympathetic ganglion cells were thought to be less 
important and the tumour was classified as a type of glioma. Only at the 
beginning of the 20th century James Homer Wright recognised the tumour 
originates from primitive neuronal cells and coined the term “Neuroblastoma”, 
as the cells were associated with fibrils similar to neuroblasts [Lee et al., 2002]. 
Felix Marchand recognized that NBL is a tumour that arises from the 
sympathetic nervous system and the adrenal gland [Cheung, 2005]. In 1953 the 
paediatric surgeon Robert E Gross opined that “extensive and radical surgery 
has a definite place under certain circumstances and can lead to permanent 
cure” [Gross et al., 1959].  
From the beginning of the 20th century there have been many attempts to make 
a prognostic evaluation from the histological features of this tumour [Beckwith 
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and Martin, 1968; Mäkinen 1972; Wahl 1914; Landau 1911]. A grading system 
proposed by Hughes was not successful [Hughes et al., 1974]. In 1983, 
Shimada proposed a classification system that was based on the unique 
principle of age-linked evaluation of morphological indicators [Shimada et al., 
1984]. In 1992 Joshi et al proposed histological grading using the mitotic rate 
(MR: low ≤10/10 high power field, high >10/10 high-power fields) and 
calcification [Joshi et al., 1992]. In 1994 the International Neuroblastoma 
Pathology Committee was created to establish a prognostically significant and 
biologically relevant classification. Five years later in 1999 the Committee 
developed the International Classification based on the original Shimada 
Classification with some modifications [Shimada et al., 1999], (see Chapter 
1.2.5). 
1.2.2 Aetiology of neuroblastoma 
Numerous studies evaluated the potential risk factors for neuroblastoma, but no 
causal factors were identified. The role of birth characteristics and reproduction 
history has been extensively studied [Yang et al. 2000]. Inconsistent results 
were reported concerning maternal history of prior miscarriage, caesarian 
section and vaginal infection during pregnancy, as well as sexually transmitted 
diseases [Michalek et al., 1996]. A recent review found no increased overall risk 
for neuroblastoma in children born after assisted conception [Williams et al., 
2013]. Reports also conflict   regarding the relationship between pre-term birth 
(<37 weeks gestation) and low birth weight (<2500 gr), [Johnson and Spitz, 
1985; Hamrick et al., 2001]. No correlation was found between parental 
occupation and the cancer [Bunin et al., 1990]. Studies from Toronto suggest 
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that the rate of neuroblastoma was reduced by 60 % with the mandatory folic 
acid fortification of flour and by multivitamin supplementation [French et al., 
2003; Goh et al., 2007]. 
 
1.2.3 Clinical and surgical features 
Neuroblastoma is described as enigmatic as it can present in several ways 
depending on the site of the primary tumour, presence of metastasis and 
production of metabolic by-products [Cheung, 2005]. It commonly presents with 
an abdominal mass, pain and distension. Hypertension is present in 25 % of 
children due to the production of catecholamine and encasement of renal 
vessels. Bone pain and limp are the result of metastatic disease in the bones. 
General cancer symptoms such as weight loss, fever and anaemia are often 
present. Tumours in the paraspinal region can present as tetraplegia due to the 
extension in the intervertebral foramen and compression of the spinal cord. 
When the growth is in the neck and involves the stellate ganglion it can cause 
Horner syndrome with miosis, ptosis and enophtalmos and heterochromia of 
the iris. Bone metastasis of the orbit causes bilateral ecchymosis called 
“raccoon eyes” or “panda eyes” [Cheung, 2005]. Patients with stage I or II 
disease and mediastinal tumours often present with cerebellar ataxia with 
opsomyoclonus and nystagmus (involuntary muscle contractions and random 
movements of the eye). This is believed to be caused by an autoimmune 
response with the production of antigen-antibody complexes that cross-react 
with Purkinje cells of the cerebellum. These are some of the more common 
clinical manifestations of this tumour. Rarely neuroblastoma can present as a 
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“mirror-syndrome” when foetal catecholamine induces symptoms in the mother 
via the placenta. In addition there are distinct associations of neuroblastoma 
with other disorders such as neurofibromatosis type 1 [Origone et al., 2003], 
Beckwith-Wiedermann syndrome [Shuman et al., 1993], Hirschsprung’s 
disease (Maris et al., 2002; Raabe et al., 2008], Ondine’s syndrome [Stovroff et 
al., 1995] and cardiovascular malformations [Lin et al., 2005; George et al., 
2004]. Some of these relationships have been explained on the basis of the 
abnormalities of neuronal crest development (see 1.2.8). 
The paediatric surgeon plays an essential role in the management of children 
with neuroblastoma. Not only is the paediatric surgeon often the first physician 
to examine a symptomatic child and raise the suspicion of this cancer, but is 
required to provide an adequate tissue sample for histological and molecular 
diagnosis and, importantly, conduct good tumour resection. Surgical removal of 
neuroblastoma is frequently a very challenging task and the mainstay of 
treatment. It requires a safe resection with full preservation of adjacent organs 
and vital structures, such as vessels and nerves. The tumour encases the 
major vessels, making en-block resections often impossible, however, invasion 
is very rare; it has not been reported to go beyond the adventitia and media. 
Surgical resection can be the only treatment required for low-risk 
neuroblastomas but it is also widely accepted that aggressive resection of loco-
regional disease should be attempted to reduce the mass of the disease. 
Haase reported that surgical resection for stage III tumour can downstage the 
patient, thereby improving the outcome [Haase et al., 1989].  
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1.2.4 Histopathology 
Neuroblastoma belongs to the tumours of peripheral neuroblastoma group and 
comprises a distinct entity from the other “small blue round cell” tumours, 
central primitive neuroendocrine tumours (cPTEN) and Ewing’s 
sarcoma/peripheral primitive neuroendocrine tumour (pPTEN), despite some 
immunological overlaps.  
In 1999, the International Neuroblastoma Pathology Committee (INPC) made a 
recommendation for terminology and morphological criteria of peripheral 
neuroblastic tumours by adopting the modified Shimada Classification 
[Shimada et al., 1999]. The INPC is a morphological classification designed to 
be prognostically significant and biologically relevant, that was established in 
1999 [Shimada et al., 1999] and revised in 2003 [Peuchmaur et al., 2003]. It 
classifies two prognostic groups; i.e. favorable histology (FH) and unfavorable 
histology (UH) groups. The histological features are evaluated from tissue 
removed by surgery or biopsy before starting chemotherapy/irradiation therapy. 
Metastatic sites are also eligible for MKI (Mitosis Karyorrhexis Index) 
calculation, except for bone marrow.  
The peripheral neuroblastic tumours are divided into 4 categories, and two 
distinct prognostic groups (‘favourable histology’ and ‘unfavourable histology’), 
based on grade of neuroblastic differentiation, Schwannian stromal 
development and mitotic karyorrhexis index, (Table 1.1). The four categories 
are: 
• Neuroblastoma (Schwannian stroma poor) 
• ganglioneuroblastoma intermixed (Schwannian stroma rich) 
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• ganglioneuroblastoma nodular (composite, Schwannian stroma 
rich/stroma dominant/stroma poor) 
• ganglioneuroma (Schwannian stroma dominant, mature or maturing). 
 
 
International Neuroblastoma Pathology 
classification  
Original 
Shimada 
classification  
Prognostic 
group  
Neuroblastoma (Schwannianstroma-poor) Stroma-poor  
 Favourable Favourable Favourable 
 <1.5 yrs 
Poorly differentiated or 
differentiating & low or 
intermediate MKI tumour 
  
 1.5–5 yrs Differentiating & low MKI tumour   
 Unfavorable Unfavourable Unfavourable 
 <1.5 yrs a) undifferentiated tumour   b) high MKI tumour 
 1.5–5 yrs 
a) undifferentiated or poorly 
differentiated tumour   b) intermediate or high MKI 
tumour 
 ≥5 yrs All tumours   
Ganglioneuroblastoma, 
intermixed (Schwannianstroma-rich) 
Stroma-rich 
Intermixed 
(favourable) 
Favourable 
Ganglioneuroma (Schwannianstroma-dominant)   
 
Maturing  
Well 
differentiated 
(favourable) Favourable 
 
Mature  Ganglioneuroma  
Ganglioneuroblastoma, 
nodular 
(composite 
Schwannianstroma-
rich/dominant/poor) 
Stroma-rich 
nodular 
(unfavourable) 
Unfavourable 
 
Table 1.1 Prognostic evaluation of peripheral neuroblastic tumours according to 
the International Neuroblastoma Pathology Classification (Shimada System) 
[Shimada H et al., 1999b]. 
MKI: mitosis-karyorrhexis index 
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1.2.5 Staging and Classification 
Over the years there have been several staging systems proposed for 
neuroblastoma. The International Neuroblastoma Staging System (INSS) 
developed by Brodeur et al. (Brodeur et al., 1988, Brodeur et al., 1993) 
classifies patients into stages 1-4s and takes into account the local and distant 
extent of the disease as well as the surgical resectability of the tumour (Table 
1.2). This is a post-operative staging system that takes into account tumour 
size and location relative to the midline and the presence of metastatic disease. 
However, it depends on the extent of surgical resection of the primary tumour in 
patients with non-metastatic disease. Recently, a new staging system was 
developed that takes into account pre-treatment imaging of the tumour and 
bone marrow pathology, instead of surgical resection, which is surgeon 
dependent and thus varies from institution to institution (Table 1.3), [Monclair et 
al., 2009]. 
Stage Description 
1 Localised tumour confined to area of origin; complete excision, with or without microscopic residual disease; ipsilateral and contralateral lymph nodes negative (nodes 
attached to primary tumour and removed en-bloc with it might be positive)  
2A Unilateral tumour with incomplete gross excision; ipsilateral and contralateral lymph 
nodes negative 
2B Unilateral tumour with complete or incomplete excision; positive ipsilateral, non-adherent 
regional lymph nodes; contralateral lymph nodes negative 
3 
Tumour infiltrating across the midline with or without lymph node involvement; or 
unilateral tumour with contralateral lymph node involvement; or midline tumour with 
bilateral lymph node involvement or bilateral infiltration (unresectable). The midline is 
defined as the vertebral column.  
4 Dissemination of tumour to distant lymph nodes, bone, bone marrow, liver, or other 
organs, except as defined for stage 4S 
4S 
Localised primary tumour as defined for stage 1, 2A or 2B with dissemination limited to 
liver, skin, and/or bone marrow (limited to infants younger than 1 year). Marrow 
involvement should be minimal (i.e., <10% of total nucleated cells identified as malignant 
by bone biopsy or by bone marrow aspirate). More extensive bone marrow involvement 
would be considered stage 4 disease. The results of the MIBG scan, if performed, 
should be negative for disease in the bone marrow. 
 
Table 1.2 The International Neuroblastoma Staging System (INSS) of 
neuroblastoma. 
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Stage Description 
L1 Localised tumour not involving vital structures as defined by the list of image-defined 
risk factors and confined to one body compartment 
L2 Locoregional tumour with presence of one or more image defined risk factor 
M Distant metastatic disease (except stage MS) 
M5 Distant metastatic disease in children younger than 18 months with metastases 
confined to skin, liver, and/or bone marrow 
 
Table 1.3 The new International Neuroblastoma Risk Group Staging System 
(INRGSS).  
 
1.2.6 Prognostic factors 
Current prognostic factors used by the COG Neuroblastoma study group for 
patients stratification and assignment to protocol are: Age (<18 months vs >18 
months), Stage (1, 2 and 4s vs 3, 4), ploidy (diploid vs. hyperploid), 
International Neuroblastoma Pathology Classification (Shimada System: 
Favourable vs. Unfavourable Histology; see Table 3), MYCN status (A vs. NA), 
1pLOH (present vs. absent) and 11qLOH (present vs. absent), [Cohn et al., 
2009, Shimada et al., 1999a, Shimada et al., 1999b]. 
 
1.2.7 Current treatment strategies and outcomes 
NBL is difficult to treat despite aggressive treatment modalities. Children with 
NBL and lack of MYCN amplification have a 93 % survival rate compared to the 
10 % event-free survival (EFS) rate in children with MYCN amplification 
[Brodeur, 2003]. The majority of patients with NBL belong to the high-risk group 
and their treatment involves chemotherapy, aggressive surgical resection, 
myeloablative chemotherapy and autologous bone marrow transplantation 
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(ABMT), radiotherapy, immunotherapy and 131I-MIBG infusion. As the survival 
rates remain poor, new approaches are needed. 
 
1.3 Glycosaminoglycans (GAGs) and Heparan Sulfate (HS) 
The complex interplay between cancer cells (“the seed”) and growth factors are 
mediated in a dynamic three-dimensional extracellular matrix (ECM), (“the 
soil”), [Paget, 1889]. The ECM plays a crucial role in the tumour 
microenvironment (TME) that goes beyond the formation of a scaffold. The 
interaction between the tumour cells and their surroundings is a dynamic 
process that changes upon modification of the ECM. Several hallmarks of 
cancer, induction of angiogenesis, avoiding immune destruction and tumour 
promoting inflammation involve close interaction between malignant cells and 
the ECM [Hanahan and Weinberg, 2011]. Therefore, cancer biology can only 
be understood through a non-simplified approach that includes the study of the 
TME. Glycosaminoglycans (GAGs) are major components of the ECM and 
evidence supports their role in the progression, invasion and metastasis of 
tumours, especially in the case of heparan sulfates (HS) [Sasisekharan et al., 
2002]. GAGs are long, unbranched polysaccharides units on the cell surface 
and extracellular matrix (ECM) attached to a core protein in the form of 
proteoglycans. They bind to many growth factors, ligands and cytokines. There 
are four major classes of GAGs, hyaluronic acid (HA), keratan sulfate (KA), 
chondroitin sulfate (CS) and heparan sulfate (HS).  
HS is a linear anionic sulfated polysaccharide chain (measuring from ~5 
to ~70 kDa) and composed of alternating monosaccharide units, N-acetylated 
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or N-sulfated glucosamine units (N-acetyl D-glucosamine, GlcNAc, or N-sulfo-
D-glucosamine, GlcNS) and hexuronic acid (either D-glucuronic acid, GlcA, or 
L-iduronic acid, IdoA). There are 23 disaccharide units but not all are equally 
prevalent. HS has a domain structure, where long stretches of Glc-A-GlcNAc 
repeating units (NA domains) are intermixed with regions of higher sulfation (S 
domains) flanked by areas of intermediate levels of sulfation (NS domains) 
[Whitelock and Iozzo, 2005; Esko and Selleck, 2002]. The HS chain is then 
further modified, mainly in the N-sulfated regions, through C-5 epimerization of 
GlcA to IdoA, O- sulfation at C-3 and C-6 of GlcN and O-sulfation at C-2 of GlcA 
and IdoA [Casu et al., 2001]. There is also the recent suggestion by Rudd 
[Rudd et al., 2012] that the commonly occurring disaccharides can be explained 
by a branched biosynthetic structure in which the branch point corresponds to 
the modification of GlcA-GlcNAc to IdoA-GlcNAc, a relatively rare event or more 
commonly, GlcA-GlcNS to IdoA-GlcNS. These two events give rise to the two 
branches. All this gives HS a high structural diversity that is based on HS chain 
length, arrangement of structural features (N-, O- sulfation, N-acetylation, etc) 
and sulfation status. The blockbuster drug and anticoagulant heparin, another 
GAG family member, which contains the same disaccharide units and linkage 
type as HS, is considered to be more homogeneous and highly sulfated than 
HS [Gallagher and Walker, 1985].  On average, around 2.7 sulfate groups are 
present within the disaccharide units of heparin and 0.6-1 within HS [Hileman et 
al., 1998; Conrad 1998]. 
HS primarily controls cancer progression by regulating the interaction 
between cells and signalling molecules such as growth factors and cytokines. 
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FGF2-HS interactions are probably the best studies example. Binding of FG2 to 
its receptor causes phosphorylation of the receptor’s tyrosine kinase domain 
and causes increased growth and migration in several cancers [Su et al., 2006; 
Plotnikov et al., 1999]. In order for FG2 to bind, the HS chain requires N-
sulfated glucosamine units and 2-O-sulfated iduronic acid units [Guimond et al., 
1993; Jia et al., 2009]. Alongside, for HS to bind to FGFR they require 6-O-
sulfates glucosamine residues in addition to 2-O-sulfated iduronic acid and N-
sulfated glucosamine residues [Guimond et al., 1993; Sugaya et al., 2008]. HS 
is also essential to other signalling pathways such as Wnt [Ai et al., 2003], 
VEGF [Narita et al., 2006; Makinen et al., 1999] and TGFbeta [Lyon et al., 
1997] and FGF [Pantoliano et al., 1994; Kan et al., 1993; Yayon et al., 1991; 
Rapraeger et al., 1991]. Cancer cells have also inherently altered proteoglycan 
structures due to errors in the biosynthetic enzymes that regulate HS 
organisation. Despite the recently increased attention to the ECM, some of its 
components such as HS are still neglected. The expression profiles of the core 
proteins along with the side-chain modification enzymes (NDSTs, SULFs, etc) 
have not been fully determined in many cancers. 
 
The 6-O-sulfation of HS has been shown to be important for binding and 
activation of many signalling molecule involved in cell proliferation, adhesion 
and migration [Ori et al., 2008]. These include FGFs such as FGF1, FGF4, 
FGF7 and FGF10 [Kreuger et al., 2001; Pye et al., 2000; Ashikari-Hada et al., 
2004; Kreuger et al., 2005], HGF [Ashikari-Hada et al., 2004; Lyon et al., 1994], 
VEGF [Ono et al., 1999], PDGF [Feyzi et al., 1997], fibronectin [Mahalingam et 
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al., 2007] and chemokines. Furthermore, in the case of FGF2, although 6-O-
sulfates are not necessary for binding, they are required for promoting the 
growth factor activity [Guimond et al., 1993; Ishihara et al., 1995]. The structural 
basis for this is that the 6-O-sulfates are required for interaction of HS with the 
FGF receptor [Pellegrini et al., 2000; Schlessinger et al., 2000], and the 
functional interaction involves a protein “canyon” involving both ligand and 
receptor molecules to create specific interactions with HS motifs [Mohammadi 
et al., 2005]. It is worth noting that effects of altered sulfation on HS interactions 
and functions may be due not only to lack of essential sulfate groups for direct 
interactions, but also on altered saccharide conformation, which can be induced 
by differences in sulfation patterns and therefore indirectly altering the binding 
characteristics for proteins [Rudd et al., 2007].  
 
1.3.1 HS chain synthesis and its biosynthetic enzymes 
The synthesis of HS is a non-template enzymatic driven multi-step process. 
The synthesis of HS chains is initiated in the endoplasmatic reticulum (ER) with 
the synthesis of the core protein and continued in the Golgi apparatus using 
sugars imported from the cytoplasma. The synthesis involves a series of 
biosynthetic enzymes that form a linear polymer of repeating disaccharide of 
hexuronic acid and glucosamine with different sulfations at various points. The 
HS biosynthetic pathway has 3 stages, 1) biosynthesis of a tetrasaccharide 
linkage region, 2) chain initiation/elongation, and 3) chain modification (Figure 
1.1).  
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Stage 1: biosynthesis of the tetrasaccharide linker region of HS 
This occurs in the lumen of the Golgi apparatus and involves the attachment of 
the tetrasaccharide linker region (four monosaccharides) to a serine within the 
conserved attachment site of the core protein.  
Stage 2: chain initiation/elongation 
After the tetrasaccharide linkage region is formed, other enzymes form the HS 
chain backbone (chain initiation and polymerization). A GlcNAc residue by N-
acetyl-glucosaminyltransferase I (GlcNAcT-I) is added and the chain elongation 
proceeds by N-acetyl-glucosaminyltransferase II (GlcNAcT-II) and 
glucuronyltransferase II (GlcAT-II) activities that add (1,4) α D-GlcNAc and (1,4) 
βD-GlcA residues in alternating sequences to the polysaccharide chain [Lidholt 
et al., 1992]. The glycosyltransferases are encoded by the exostin (EXT) gene 
family [Takei et al., 2004]. The chain will now act as a substrate for modification 
by sulfotransferases in the HS biosynthesis. 
Stage 3: Chain modification 
After Stage 2 the HS backbone is composed of repeating disaccharide units of 
D-glucuronic acid and N-acetyl D-glucosamine (GlcA-GlcNAc)n that are 
unsulfated and not yet epimerized. The HS chain is then subject to further 
modifications by a series of enzymes: N-deactylase/N-sulfotransferase (NDST), 
C5 epimerase (C5-Epi), 2-O-sulfotransferase (2-OST), 6-O-sulfotransferase (6-
OST) and 3-O-sulfotransferase (3-OST). These sulfotransferases are 
membrane bound and located in the Golgi. Three different 6-O-sulfotransferase 
(6-OSTs) have been cloned, seven 3-OSTs as well as four isoforms of the 
NDSTs [Aikawa and Esko, 1999; Esko and Lindahl 2001; Habuchi et al., 2000]. 
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Only one C-5 epimerase and one 2-OST have been identified. The exact 
functionality of all the different enzymes and isoforms has not yet been 
identified. 
 
 
Figure 1.1 HS chain is biosynthesised on a core protein. Not all biosynthesis or 
modification steps occur in a linear sequence. Some modification steps depend on 
previous steps to occur first, whereas others are independent. 
 
 
Full details and regulation of the biosynthetic pathways of the HS chain are not 
entirely known. Rudd et al. [Rudd et al., 2012] proposed a novel forked 
biosynthetic pathway for HS where all common HS disaccharides are 
synthesised through a common route, the major branch, giving rise to the 
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commonly occurring disaccharides GlcA-GlcNS and subsequent modifications 
by epimerase, 2-OST and 6-OST; and a minor branch starting from IdoA-
GlcNAc, which contains the minor disaccharides.  
 
N-deactylase/N-sulfotransferase  
NDST is the first modification enzyme in the HS biosynthetic pathway. The 
actions of NDST are believed to determine the subsequent modifications, 
especially epimerization, 2-O- and 3-O-sulfation. NDST is a dual function 
enzyme. N-deacetylase activity removes the acetyl group from the GlcNAc 
residue to a GlcNH2 residue; N-sulfotransferase activity transfers a sulfo group 
to the primary amine group to form a GlcNS residue. Four isoforms of NDST 
have been identified in the human genome [Aikawa and Esko, 1999]. It is 
believed that the different isoforms have different substrate specificities, and 
knockout experiments in mice have begun to distinguish their in vivo functions. 
NDST1 is the most expressed isoform. Conditional knockout of NDST1 showed 
several physiological roles, including the development of mammary gland 
[Crawford et al., 2010], neutrophil trafficking [Wang et al., 2005] and inhibition of 
tumour angiogenesis [Fuster et al., 2007]. The absence of NDST1 caused 
respiratory distress and neonatal death [Fan et al., 2000]. These were attributed 
to the changes in O-sulfations and epimerisation of HS. NDST2 knockout mice 
were viable but had abnormal connective tissue mast cells [Forsberg et al., 
1999]. NDST1 and NDST2 were found to be up-regulated in hepatocellular 
cancer [Tátrai et al. 2010]. NDST3 knock out mice are also fertile with subtle 
haematological and behavioural changes [Pallerla et al., 2008]. The NDST4 
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gene has been reported to be a tumour suppressor gene in human colorectal 
cancer [Tzeng et al., 2013]. The difficulty in analysing these enzymes is that the 
expression of the NDST isoforms may be both translationally and post-
translationally regulated [Grobe and Esko, 2002]. 
 
6-O-sulfotransferases 
There are three members of the HS 6-OST family. Isoform 1 is strongly 
expressed in liver, 6-OST2 mainly in spleen and brain, and 6-OST3 is 
expressed throughout the body in most mouse tissues [Habuchi et al., 2000]. 
HS 6OSTs catalyze the transfer of a sulfo group to the C6 position of 
glucosamine residue (GlcN) to form 6-O-sulfo glucosamine. 6-O-sulfation 
occurs predominantly at the GlcNS residue, generating a GlcNS6S moiety. 
However, in some cases, it can also occur at the GlcNAc residue, generating a 
GlcNAc6S moiety; 6-O-sulfation is the only type of sulfation that occurs at the 
GlcNAc residue. Three isoforms of 6OST have been identified with many 
similarities. The 6-O-sulfation by 6OST1 predominantly occurs at the GlcNS 
residues, while other 6OST isoforms can modify GlcNAc to yield GlcNAc6S. 
Furthermore, 6OST1 prefers the IdoA-GlcNS over GlcAGlcNS while 6OST2 
favours GlcA-GlcNS more than IdoA-GlcNS. 6OST3 acts equally on both 
disaccharide structures. 6OST2 has two transcript variants encoding different 
isoforms [Habuchi et al., 2003]. 6OST1 null mice had growth retardation, 
abnormal lung and eye development, and impaired placental function and did 
not survive long after birth [Irie et al., 2002]. 6OST1 and 6OST2 were described 
as being overexpressed in ovarian cancer and human colorectal cancer 
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[Backen et al., 2007; Raman et al., 2010]. 6OST1 was reported to be up-
regulated in hepatocellular cancer [Tátrai et al., 2010]. The enzyme 6OST1-3 
was down-regulated, in glioblastoma [Wade et al., 2013]. 
 
2-O-sulfotransferase 
2OST transfers a sulfo group to the 2-OH position of IdoA or GlcA (with a 
preference for IdoA) within HS and is the only sulfation that occurs on the 
uronic acid units. [Kobayashi et al., 1997]. 2OST is also the only HS 
sulfotransferase that exists as a single isoform. Bullock et al described renal 
agenesis, eye and skeletal defects in 2OST-null mice, which die soon after birth 
[Bullock et al., 1998]. This enzyme may have a preference for IdoA-GlcNS over 
IdoA-GlcNAc substrates, notably just after the proposed  “branch” in the 
pathway [Rudd et al., 2012]. A report in the literature shows that this enzymes 
is over-expressed in prostate cancer cell lines and tissue, where its expression 
correlates with increasing metastatic potential [Ferguson and Datta, 2011].  
 
3-O-sulfotransferase 
The last family of enzymes that are involved in the HS modification are the 3-O-
sulfotransferase with seven different isoforms [Shworak et al., 1997; Shworak et 
al., 1999; Mochizuki et al., 2003]. The 3-OSTs catalyze sulfuryl transfer to the 
3-hydroxyl position of various glucosamine residues. 3-O sulfation of 
glucosamine residues of HS occurs with low frequency. Alterations of these 
enzymes have been reported in various tumours. Methylation-associated 
silencing of the isoform 3-OST2 was found in primary human breast, colon, lung 
 22 
and pancreatic cancer [Miyamoto et al., 2003] and in malignant melanoma 
[Furuta et al., 2004]. Furthermore, down regulation of isoforms 3-OST4, 3-OST5 
and 3-OST6 have been reported in invasive breast ductal carcinoma 
[Fernandez-Vega et al., 2013].  
 
1.3.2 Remodelling of HS chain and Sulfotransferases (SULFs) 
The synthesized HS chain is released from the cell in proteoglycan form and 
located on the cell surface or in the ECM [Iozzo, 2005]. HSPGs on the cell 
surface can either be shed by cleavage of the core protein or by cleavage of the 
HS chain by extracellular heparanase. Bound ligands can so be released to 
diffuse away from the cell. Until recently it has been thought that no further 
modification of HS occurs but, the discovery of a novel class of enzymes that 
edit the 6-O sulfation status, has altered that view [Dhoot et al., 2001; 
Morimoto-Tomita et al., 2002]. In fact, additional control of the HS structure 
takes place at the cell surface, where degrading enzymes modify post-
synthetically the HS chain.  
The sulfatase enzymes SULF1 and SULF2 change the sulfation status of 
HSPGs outside the cell. SULF1 was identified for the first time in quail embryos 
in  [Dhoot et al., 2001], SULF2 was cloned later from mouse and human 
[Morimoto-Tomita et al., 2002]. The substrate specificity of the SULFs is 
unclear. However, they remove the 6-O sulfate groups from HS (GlcNS) with 
preference for the 6-O sulfate present on trisulfated disaccharides (IdoA2S-
GlcNS6S) within S-domains of HS and to a lesser extent on disulfated 
disaccharides (UA-GlcNS6S) [Ai et al., 2003; Lamanna et al., 2008]. No effect 
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on other 6-O sulfate disaccharides was observed, implying a requirement for N-
sulfate groups. However, it is still unclear if SULF2 has substrate specificity for 
other disaccharide motifs in HS. No effects on other 6-O sulfated disaccharide 
were observed. Studying knock-out mice gave some information; single SULF1 
or SULF2 knock out mice had normal viability and no phenotypical and 
histological changes, suggesting an overlapping function of the two enzymes. 
However, double SULF1/2 knock-out mice had several congenital abnormalities 
and a higher neonatal mortality rate [Lamanna et al., 2006; Lamanna et al., 
2008; Ai et al., 2007; Holst et al., 2007].  
Both SULFs are very similar in structural organisation but divergent in 
sequence identity and their biochemical activities are still controversial. SULFs 
differ from other sulfatase enzymes, as they are extracellular endosulfatase 
(intra-chain) enzymes that act at neutral pH. This differs from lysosomal 
sulfatases, which are active in an acid environment and remove sulfate esters 
from the termini of chains [Morimoto-Tomita et al., 2002; Rosen and Lemjabbar-
Alaoui, 2010].  
SULFs are large proteins of approximately 870 amino acids (aa) with a unique 
structural organisation consisting of four domains: a cleavable signal peptide, a 
catalytic domain (CAT), a central hydrophilic domain (HD) and a C-terminal 
region (C-ter) [Morimoto-Tomita et al., 2002; Tang and Rosen, 2009]. The 
signal peptide and two sulfatase-related domains (approx. 374 aa and 118 aa) 
are separated by a hydrophilic domain (HD) of approx. 350 aa. SULFs are 
formed as pre-proteins (125 kDa). The pro-protein is cleaved within the 
hydrophilic domain by a furin-type proteinase resulting in 75 kDa and 50 kDa 
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fragments [Uchimura et al., 2006], which are then joined by disulfide bonds 
(Figure 1.2). It has been shown that this cleavage is essential for activation of 
SULF2 [Nagamine et al., 2010].  Blocking the furin cleavage had little or no 
effects on the secretion of the SULFs and enzymatic activity. However the 
localisation of the SULFs into the lipid rafts was reduced when furin-type 
cleavage was prevented [Tang and Rosen, 2009]. An altered localisation of the 
SULFs in the lipid rafts could be responsible for optimal signalling and possible 
non-enzymatic functions of the SULFs. The exact functions of the furin-type 
cleavage of the SULFs are unknown. CAT domain is highly homologous to the 
conserved catalytic domains of all eukaryotic sulfatases. The CAT domain is 
located in the amino-terminal 75 kDa unit and contains a post-translational 
modification, an α-formylglycerin (FGy) residue resulting from oxidation of a 
conserved cysteine, which is essential for enzyme activity (critical cysteine 
residue “C”), [Dierks et al., 1997]. The HD domain is the unique feature of the 
SULFs, has no homology with any other protein sequences and is essential for 
recognition and endosulfatase activity on HS and for cell surface localisation of 
the SULFs. Mutated SULF enzymes with deleted HD domains have 
arylsulfatase activities, but lack endosulfatase activity against HSPGs [Tang 
and Rosen, 2009]. The C-ter domain has unknown function but, it has 
homology with the C-ter region of the lysosomalsulfatase. The C-ter 50 kDa 
subunit is required for both the arylsulfatase and the endosulafatse of the 
enzymes. SULF1 and SULF2 are highly homologous in all domains, consistent 
with their unclear functional differences. The SULFs and particularly SULF2 
have been shown to regulate the interaction of many ligands with HS such as 
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VEGF, FGFs, TGF, SDF-1 (CXCL12), [Ori et al., 2008]. Through their ability to 
regulate the 6-O sulfation in the functional S-domains of HS, the SULFs can 
regulate ligand binding/activation, which can result in enhancement or 
repression of signalling. This depends on the isoform (SULF1 or SULF2) the 
protein ligands and the biological context. For example, quail SULF1 was 
initially identified for its ability to promote Wnt signalling because its action 
reduced its affinity for Wnt enabling the formation of a HS/Wnt/Frizzled 
functional complex [Ai et al., 2003]. Similar SULFs enhance BMP signalling by 
regulating its inhibitor Noggin [Otsuki et al., 2010; Viviano et al., 2004]; and 
GDNF during neuronal development [Ai et al., 2007]. In contrast SULFs down 
regulate FGF1, VEGF, TGFβ [Ashikari-Hada et al., 2004; Ori et al., 2008]. 
Additionally, SULF1 has been shown to either enhance or repress sonic 
hedgehog (Shh) during neuronal development [Danesin et al., 2006]. SULFs 
are well expressed in embryonic tissues [Danesin et al., 2006; Dhoot et al., 
2001]. In zebrafish both SULFs were broadly expressed in various tissues, 
whereas SULF2 expression was entirely restricted to the CNS [Gorsi et al., 
2010]. During embryogenesis, SULFs also promote oesophageal innervation, 
bone skeletal system [Ai et al, 2007; Holst et al., 2007; Lamanna et al., 2006]. 
In the mouse embryo at E14.5 and E16.5, SULF1 and SULF2 were expressed 
in many embryonic tissues, including the floor plate of the neuronal tube, bone, 
cartilage, skeletal muscle and lung [Ai et al., 2007].  Interestingly, SULF1 and 
SULF2 were reported to be essential for neuronal crest migration in vivo in 
Xenopus tropicalis [Guiral et al., 2010]. 
However, the distinct roles of the two isoforms SULF1 and SULF2 are not well 
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understood. First, one of the enzyme could be more labile than the other 
resulting in low steady stale levels in some organs/tissues. Second, the activity 
of one of the SULFs could be inhibited by unknown factor(s). Third, one of the 
enzymes could be more diffusible and thus able to desulfate more HS in some 
particular environments; fourth, SULF1 and SULF2 could undergo different 
protein cleavage in vivo [Tang and Rosen, 2009]. Fifth, native HS may have 
distinct structures that are more susceptible to desulfation by either SULF1 or 
SULF2.  
 
Figure 1.2 SULF synthesis as a pre-protein. The yellow star indicates the conserved 
sulfatase-specific cysteine residue necessary for enzyme activity.  
 
1.3.3 SULFs in cancer 
Increasing evidence indicates an important role for the SULFs in cancer [Bret et 
al., 2011; Rosen and Lemjabbar-Alaoui, 2010].  Elevated SULF2 levels have 
been correlated to aggressive hepatocellular cancer (HCC) [Yang et al., 2011], 
pancreatic cancer [Rosen and Lemjabbar-Alaoui, 2010], head and neck 
squamous cell carcinoma [Bret et al., 2011], gastric cancer [Hur et al., 2012], 
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non-small-cell lung carcinoma (NSCLC) [Lemjabbar-Alaoui et al., 2010], 
oesophageal cancer [Lui et al., 2012], glioblastoma multiforme [Phillips et al., 
2012]. Overall, it was shown that an overexpression of SULF1 reduces the 
growth of cancer cell lines [Lai et al., 2003]. Low SULF1 expression levels were 
found in hepatocellular carcinoma (HCC), specific types of breast cancer, 
kidney, gastric and bladder cancers [Lai et al., 2003; Lai et al., 2004; Rosen 
and Lemjabbar-Alaoui, 2010]. Some reports showed an overexpression of 
SULF1 in gastric, pancreatic, brain, oesophageal and lung carcinoma [Bret et 
al., 2011; Nawroth et al., 2007; Lui et al., 2012; Rosen and Lemjabbar-Alaoui, 
2010]. SULF2 has been shown to reverse ligand interactions with heparin 
causing their release. It is this mechanism that allows cells that secrete SULF to 
communicate with their tumour microenvironment by releasing sequestrated 
growth factors that can then act back to the cell. By this action they can activate 
multiple key signalling pathways (e.g., Wnt, Shh and PDGF). SULFs seem to 
have overlapping function in development where, despite their role in regulating 
many signalling pathways, they do not seem to be obligatory. In cancer the 
SULFs seem to be a driver of carcinogenesis. Such examples are given by 
FGF-2 dependent proliferation of tumours [Turner et al., 2010]. HS reduces the 
binding of GDNF to HS allowing the interaction with its receptor to produce 
GDNF signalling [Davies et al., 2003]. Recently, SULF2 was identified as a 
transcriptional target of the tumour suppressor p54 [Chau et al., 2009].  
Of the two isoforms, SULF2 has been shown to be a more attractive therapeutic 
target for cancer due to its overexpression in several tumours [Rosen and 
Lemjabbar-Alaoui, 2010; 2010; Bret et al., 2011; Lui et al., 2012]. SULF2 
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antagonists may be particularly valuable in ligand-dependent tumours. SULF2 
is an extracellular enzyme where it can be easily targeted by low molecular 
weight compounds, making it a druggable target. SULF2 as targets for 
anticancer therapies are discussed in Chapter 6.  
 
1.4 The MYCN oncogene 
MYCN is member of the MYC family and is a DNA binding helix-loop-
helix/leucin zipper protein that forms an obligate heterodimer with the partner 
protein MAX [Wenzel et al., 1991]. MYCN and MAX contain DNA binding motifs 
and the active protein initiates transcription when bound to its DNA binding 
sires of which the E-box motif is the most frequent [Thomas et al., 2004]. The 
exact mechanism that MCYN uses to mediate its oncogenic effects is not 
exactly known. It is known that MYCN amplification increases cell proliferation 
by shortening the time used to progress through the cell cycle [Dang, 2012]. 
MYCN is also known to increase the susceptibility of cells entering apoptosis 
after cell stress such as DNA damage and hypoxia and to increase genomic 
instability [Leder et al., 1986]. MYCN establishes a delicate balance between 
pro- and anti-apoptotic molecules that might be easily perturbed by various 
insults [Leder et al., 1986]. The guardian of the genome p53 has been reported 
to be a direct transcriptional target of MYCN [Carr-Wilkinson et al., 2011]. 
MYCN is also a transcriptional activator of MDM2, which is a negative regulator 
of p53 [Slack and Shohet, 2005]. Deregulated expression of MYCN can also be 
present without MYCN amplification, as MYCN is downstream of other 
oncogenic signal transduction pathways [Valentijn et al., 2012].  The apoptosis-
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sensitive phenotype induced by MYCN via the MDM2-p53 pathway is relatively 
rare in NBL as p53 is rarely mutated [Keshelava et al., 2001; Moll et al., 1995]. 
The mechanisms by which MYC family members induce apoptosis are not fully 
understood. It is known that MYCN overexpression induces apoptosis in cells 
from the nervous system but not so frequently in NBL cells [Lutz et al., 1998]. 
Knocking MYCN out in MYCN-addicted tumours represents a very effective 
therapeutic strategy [Puissant et al., 2013]. MYCN induced SULF2 transcription 
may be another important mechanism by which MYCN sensitises cells to 
proliferation or apoptosis. 
 
1.4.1 MYCN in development and neuroblastoma 
MYCN is a strong oncogene that is naturally expressed only in embryonic life 
particularly neural tissue [Schwab, 2004]. During development MYCN is 
expressed at gastrulation and other early stages of embryogenesis before 
neurulation and somitogenesis [Moodley et al., 2013]. During later stages of 
development MYCN expression becomes limited to the peripheral and central 
nervous system and structures derived from the neuronal crest. Mice with a 
deletion of MYCN have a reduced number of mature neurons in the 
sympathetic ganglia during embryonic development [Soucek et al., 2008; 
Arvanitis and Felsher, 2006]. MYCN is responsible for tumour progression and 
expansion and induces genomic instability in cell culture [Whitfield and Soucek, 
2012]. 
 MYCN was one of the first genetic defects identified in NBL and high levels 
and/or amplification are associated with aggressive tumour phenotype and poor 
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survival [Slamon et al., 1986]. MYCN is the strongest indicator for aggressive 
tumour progression and is observed in 15 to 20 % of all NBL tumours with 
amplification, meaning an increase of the gene copy number. MYCN has 
recently also been identified in adult tumours such as, retinoblastoma, prostate 
cancer and triple-negative breast cancer [Dang, 2012; Gurel et al., 2008; 
Palaskas et al., 2011]. MYCN amplification refers to the increased number of 
copies of the gene within a cell. MYCN amplified (A) NBL cells usually have 
between 50 to 100 extra copies of the gene, DNA amplicons are identified by 
fluorescence in-situ hybridisation (FISH) analysis. 
 
1.4.2 MYCN therapeutic targets 
MYCN has long been regarded as an undruggable target. Normal proliferating 
cells also use MYCN for renewal. Several strategies aimed to interrupt the 
MYCN-MAX dimerization [Clausen et al., 2010; Follis et al., 2008; Brockmann 
et al., 2013; Park et al., 2004], to inhibit MYCN-MAX DNA binding and to 
interfere with key MYCN target genes such as repression of miR-26a have 
been proposed [Kota et al., 2009]. Interestingly, recent reports showed that an 
inhibitor of the BET bromodomain inhibited MYCN and impaired growth and 
inducted apoptosis in NBL [Puissant et al., 2013]. 
 
1.5 Research Objectives  
The main hypothesis of this study is that HSPGs and their sulfation status are 
involved in the regulation of NBL cell survival. Identifying alterations in HSPG 
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structure “signatures” and their effects on tumour behaviour represents a 
therapeutically relevant goal, with potential impact in the clinic. 
The objectives of this study are to: 
1. Examine the expression of HS and its biosynthetic enzymes in different 
NBL cell lines. Work under this aim will help to establish the relevance of 
different populations of NBL tumour cells and their HS profile, and may 
lead to a novel marker/s.  
2. To validate the findings in primary human NBL tissue and identify any 
correlation to clinical outcome and behaviour. Work with this aim is 
concerned with extending the observation from the in-vitro to the human 
in-vivo situation. 
3. Investigate the effects of the alteration of HS sulfation on the activity of 
NBL cell lines in vitro by knock-down and over-expression techniques. 
Work with this aim will highlight the importance such HS changes in NBL 
cell survival and introduce the possibility of new therapeutic targets. 
4. To identify any possible association between HSPGs profile and a 
clinically relevant marker of poor outcome, such MYCN amplification. 
Work with this aim may lead to the development of a clinical relevant link 
between sulfation status and outcome.  
 
1.6 Thesis overview 
This thesis will explore the role of HS and its sulfation status in NBL. It provides 
the first report of the implications of Sulfotransferase 2 (SULF2) levels in NBL 
cell survival and a link to the proto-oncogene MYCN, a marker of poor outcome. 
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The subsequent Chapters of this thesis will deal with each of the Specific 
objectives as follows:  
Chapter 1 provides an introduction to the research work presented in this 
thesis. It describes the research background and objectives. 
Chapter 2 will describe the materials and methodologies used. 
Chapter 3 will focus on the expression of HS biosynthetic enzymes in a series 
of NBL and other cancer cell lines. A candidate enzyme amongst several 
biosynthetic and modification enzymes that modify the HS chain (SULF2) is 
identified in NBL cell lines with amplification of the MYCN oncogene (MYCN-A).  
Chapter 4 analyses the effects of SULF2 alteration on modulating the biological 
behaviours of NBL cells such as cell proliferation and survival. Reduction of 
SULF2 expression in NBL cells was demonstrated to significantly reduce the 
proliferation of MYCN-A NBL cells and increase apoptosis. SULF2 was shown 
to be a down-stream target of MYCN by demonstrating that over-expression of 
MYCN in NBL cell lines increases SULF2 expression and vice versa 
(Knockdown of MYCN reduced the expression of SULF2).  The importance of 
SULF2 in neuroblastoma survival was then demonstrated independently of 
MYCN by over-expressing SULF2 in MYCN-NA NBL cells resulting in an 
increase in cell viability without increasing MYCN expression. 
Chapter 5 describes the expression of SULF2 in in a large panel of primary 
human NBL tumour tissue with and without MYCN-A. Additional data from a 
large cohort of human tumours confirms the gene expression of SULF2 in high-
risk patients with MYCN amplified NBL. Here we also show the effects of 
SULF2 knockdown in a mouse model on NBL.  
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Chapter 6 will include a general discussion of the thesis results, present 
suggestions for future directions and work, with particular reference to 
translational applications. 
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Chapter 2: Material and Methods 
 
2.1 Cell lines and cell cultures 
Eight human NBL cell lines with and without MYCN amplification and other 
human cell lines were grown under established conditions at 37 °C in a 
humidified incubator containing 95 % air and 5 % CO2 atmosphere. Human NBL 
cell lines CHLA-255, CHLA-255-MYCN, CHLA-90, CHLA-16, SMS-SAN and 
SK-N-RA were cultured in complete medium consisting of Iscove’s modified 
Dulbecco’s medium (IMDM) supplemented with 20 % FCS, 2 mM L-glutamine 
and penicillin (100 U/ml) and streptomycin (100 µg/ml), (pen/strep). Cell lines 
NB-19, SK-N-BE2, A549, HT-1080, SHEP, SHEP-2, SHEP-21N, HT-1080 and 
HBMEC were grown in RPMI-1640 (Mediatech) supplemented with 10 % 
(vol/vol) FCS with penicillin-streptomycin (pen-strep; Invitrogen). Cell line SK-
NSH, HeLa, C8161 and fibroblasts, were grown in DMEM with 10 % FCS and 
penicillin-streptomycin. The cell lines used are shown in Table 2.1. 
To facilitate mycoplasma detection (MycoAlertMycopplasma Detection Kit; 
Lonza, #LT 07-418) cells were grown without antibiotics for at least 2 passages, 
for which all of the cells tested negative. Cell lines’ identity was confirmed by 
genotype analysis using AmpFISTR Identifier kit PCR Reagents and Gene 
Mapper ID v3.2 (Applied Biosystems). 
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Cell line Type MYCN  Stage Age Therapy  Tissue 
source 
References 
CHLA-
255 Neuroblastoma NA 4 − 
PD + 13-
cis   Brain 
Keshelava et 
al., 1998 
CHLA-
255-
MYCN 
Neuroblastoma 
transfected A★ − − − − Song et al., 2007 
CHLA-90 Neuroblastoma NA 4 102 m PD-BMT Bone marrow 
Keshelava et 
al., 2001 
SK-N-SH Neuroblastoma  NA 4 48 m PD − ATCC HTB-11 
SHEP Neuroblastoma subclone NA 4  PD 
Bone 
marrow 
Biedler et al., 
1978 
SHEP-2N Neuroblastoma transfected NA − − − − Lutz et al., 1996 
SHEP-tet 
21N 
Neuroblastoma 
transfected A
★ − − − − Lutz et al., 1996 
NB-19 Neuroblastoma NA 4 12 m PD Bone marrow Riken  
CHLA-
136 
Neuroblastoma A 4 36 m PD-BMT Bone marrow 
Keshelava et 
al., 2001 
SK-N-
BE2 
Neuroblastoma A 4 24 m PD Bone marrow ATCC CRL-227 
SMS-
SAN 
Neuroblastoma A 4 36 m Dx Bone marrow 
Reynolds et al., 
1986 
SK-N-RA Neuroblastoma A 4 - PD Bone marrow 
Keshelava et 
al., 1998  
Cell line Type MYCN  Morphology Age    Tissue source References  
HeLa Adenocarcinoma NA epithelial 31 y Cervix ATCC CCL-2 
A549 Lung squamous carcinoma 
NA epithelial 58 y Lung ATCC CCL-185 
MG-63 Osteosarcoma NA fibroblast 14 y Bone ATCC CRL-1427 
MDA-MB-
231 
Human Breast 
adenocarcinoma 
NA epithelial 51 y Pleural effusion ATCC HTB-26 
HT-1080 Human Fibrosarcoma 
NA epithelial 35 y Connective tissue ATCC CCL-121 
C8161 Human Melanoma 
NA epithelial Middle age 
Abdominal wall 
metastasis 
Bregman and 
Meyskens, 1983  
Fibroblast Human foreskin NA fibroblast Newborn foreskin ATCC CRL-2522 
HBMEC Brain endothelial 
NA 
endothelial Unknown Brian cortex 
ScienCell 
Research 
Laboratories 
#1000  
HEK 
293T 
Human 
embryonic 
kidney 
NA 
Epithelial Fetus Embryonic kidney ATCC CRL-1573 
 
Table 2.1 Cell lines and culture conditions used. 
Dx (Diagnosis) = cell lines derived from samples of patients prior treatments 
PD (Progressive disease) = cell lines derived from samples of patients who relapsed after chemotherapy 
PD-BMT =  cell lines derived from samples of patients who relapsed after chemotherapy and bone marrow 
transplant 
13-cis = 13-cis-retinoic acid 
m = months; y = years 
NA = non-amplified; A = amplified 
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2.2 Real-Time Reverse transcription (RT)-PCR  
RNA was isolated from lysed cells using aRNeasy® Mini kit (Qiagen, #74104) 
according to the manufacturer’s protocol ‘Purification of total cellular RNA’. The 
NanoDropTM ND-100 Spectrophotometer (Nano Drop Technologies, Inc., USA) 
was used to determine the concentration and to assess the quality of the RNA 
(absorbance ratio 260 nm : 280 nm between 1.9 and 2.1). 
Total RNA (1µg) was reversed transcribed using Superscript III Reverse 
Transcriptase (Invitrogen, # 18020-051) according to the instructions provided 
by the manufacturer.  
Gene expression of enzymes involved in the HS chain regulation was 
performed using LightCycler® 480 (Roche); [Table 2.2]. The expressions of 
RNA were measured against the housekeeping genes GAPDH and β-actin. 
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Abbreviation Gene Oligonucleotides RefSeq No 
2OST1 F 2-O-Sulfotransferase-1 TCTTGGAAAACCAGATCCAGA NM_012262.3 
2OST1 R  CTCGGACTTCGTGTCTTGC  
3OST1 F 3-O-Sulfotransferase-1 CCAGCCCAGGAGCCTATT NM_005114 
3OST1 R  CAGCAGGGAAGCCTCCTA  
3OST2 F 3-O-Sulfotransferase-2 GGATTCCCTTGCTTGAAAAA NM_006043 
3OST2 R  TTTTGATTTGCCCAAGCATC  
6OST1 F 6-O-Sulfotransferase-1 CTCTTCTCCCGCTTCTCCA NM_004807 
6OST1 R  CTCGTAGCAGGGTGATGTAGTAGA  
6OST2L F 6-O-Sulfotransferase-2 l CAAAGACCCGGAACACATCT NM_001077188 
6OST2L R  CTCAAGTACCGGGACACTGG  
6OST2S F 6-O-Sulfotransferase-2 s TGCGATCTTCTCCAAGATTTTC NM_147175 
6OST2S R  ACGATCACGGCAAATAGGAA  
6OST3 F 6-O-Sulfotransferase-3 TCTTCTCCCGCTTCTCCA NM_153456 
6OST3 R  CCCGTAACATTGTGATGTAATAGAA  
SULF1 v1 F Sulfatase-1 variant 1 CGCTGCCACCTTATCTCTG NM_001128205.1 
SULFf1 v1 R  TGTTCAAGAGAAGTGAAGAATCCA  
SULF1 v2 F Sulfatase-1 variant 1 CAGACAGCCTGTGAACAACC NM_015170.2 
SULF1 v2 R  ATTCGAAGCTTGCCAGATGT  
SULF2 v1 F Sulfatase-2 variant 1 GTGACAGCGGGGACTACAAG NM_018837 
SULF2 v1 R  CGACTGCGGACATAGCTG  
SULF2 v2 F Sulfatase-2 variant 1 CGAATCCCACATCTGTTTCA NM_198596 
SULF2 v2 R  CCCTCTTCACTCGCAGATTC  
NDST1 F NDST1 CACAAAGGCATCGACTGGTA NM_001543.4 
NDST1 R  AGAAGTCGGAGGTGGTGTTG  
NDST2 F NDST2 CAGGCCTGACGTCGAATC NM_003635.2 
NDST2 R  GTCAGCAAAGTTCAATCTCTTCC  
NDST3 F NDST3 CACAGGGGGATTGATTGGTA NM_004784.2 
NDST3 R  CAAACAAAAAGTCGGTAGTGACA  
NDST4 F NDST4 CTTGTCCCCAAAGCCAAG NM_022569.1 
NDST4 R  GGATCTTCATGTGATCGTTGG  
GAPDH F GAPDH AACGGGAAGCTTGTCATCAA NM_002046 
GAPDH R  TGGACTCCACGACGTACTCA  
Beta-actin F Beta-actin CCAACCGCGAGAAGATGA X00351 
Beta-actin R  CCAGAGGCGTACAGGGATAG  
 
Table 2.2 HS biosynthetic enzymes and their primers used for qRT-PCR. v = 
variant, L = long, S = short, F = forward, R + reverse. 
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2.3 Western Blotting 
Adherent cells were harvested in Pierce IP Lysis Buffer with the addition of Halt 
Protease Inhibitor Cocktail (Thermo Scientific, #78430). Cell lysates were left 
on ice for 20 min then cleared by centrifugation at 12,000 g for 15 min at 4 °C. 
Protein concentration was measured by the bicinchonic acid (BCA) protein 
assay kit (Pierce BCATM Protein Assay Kit; Pierce Biotechnology, #23225). 
After denaturation at 100 °C for 5 mins with a 2.5 % p-mercaptoethanol loading 
buffer, equal amounts of protein (40 µg/lane) were resolved by electrophoresis 
in a 10-20 % gradient acrylamide gel containing 0.1 % SDS (Bio-Rad 
Laboratories, #456-1084). Gels were transferred to protein nitrocellulose 
membranes (Bio-RadLaboratories, #162-0115) by semi-dry blotting. 
Membranes were blocked by Odyssey® Blocking buffer (LI-COR Biosciences, 
#927-40000) for 1 h at room temperature and then incubated overnight at 4°C 
with the primary antibody diluted in Odyssey Blocking Buffer with 0.1 % (v/v) 
Tween-20. Membranes were washed and then probed for 1 h at room 
temperature with an anti-mouse IgGIRdye 680 (LI-COR, #926-32220) and/or an 
anti-rabbit IgGIRdye 800 (Li-Cor #926-32211) as secondary antibodies at a 
dilution of 1:5000. 
2.4 Immunocytochemistry and confocal microscopy 
Cells were seeded (5 x 104 /mL) into 24-well plates on round glass coverslips 
and grown for 12-24 h then rinsed with PBS and fixed with 4 % (w/v) 
paraformaldehyde for 10 min at room temperature. After washing, non-specific 
binding was blocked with 10 % (v/v) normal goat serum for 1 h at room 
temperature. Cells were incubated overnight at 4 °C with the primary antibody 
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diluted in PBS with 1% (v/v) normal goat serum. Phage-display antibodies 
against HS (HS3B7V, HS4E4V, HS3A8V and RB4CD12) were supplied by 
Professor T. van Kuppevelt (Nijmegen, The Netherlands). Cells were rinsed 
with PBS and a rabbit polyclonal VSV-G tag antibody (Abcam, #ab1874) was 
applied (1:200 dilution v/v) for 1 h at room temperature. AlexaFluor®-488 goat 
anti-rabbit IgG (H+L) and AlexaFluor®-594 goat anti-mouse IgG (H+L) 
conjugated secondary antibodies (Life Technologies, #A-11012 and A-11001; 
respectively) were used at a concentration of 2 µg/ml in PBS with 1 % (v/v) 
normal goat serum for 1 h. Hoechst 33342 was used as a nuclear counterstain 
(1 µg/ml; Life Technologies, #H3570). Cells were mounted with ProLong (Life 
Technologies, #P36930). When double staining for SULF2 and HS with the 
phage display antibodies was performed, both primary antibodies were 
incubated together followed by VSV-G tag antibody incubation and finally by the 
secondary fluorescent conjugated Alexafluor antibodies. Controls included the 
omission of either the primary antibody or the VSV-tag (phage display 
antibodies) or pretreatment with 2.5 mU of heparinase I (from Flavobacterium 
heparinum, EC 4.2.2.2.7), heparinase II (from Flavobacterium heparinum, no 
EC number) and heparitinase (from Flavobacterium heparinum,EC 4.2.2.2.8), 
(IBEX Technologies, Montreal, Canada). Fluorescence and differential 
interference contrast (DIC) images were captured using LSM 710 confocal 
microscope with a 63 x 1.4 Plan-APOCHROMAT oil-immersion objective lens 
(Carl Zeiss Microscopy, Thornwood NY, USA).   
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2.5 Immunohistochemistry of primary NBL tumours 
Archival formalin fixed paraffin-embedded (FFPE) tissue sections of human 
primary NBL were obtained from the Children’s Oncology Group (COG) 
Neuroblastoma Biology Study with the approval of the CHLA Institutional 
Review Board. Samples were obtained without patient identification. 
Tissue section (5 μm) were deparaffinised, rehydrated and subjected to heat-
induced epitope retrieval with citrate buffer pH 6.0 using a microwave. 
Endogenous peroxidase was blocked with Bloxall (Vector Laboratories, 
#SP6000). Sections were stained using the Universal Staining Kit (Vector 
Laboratories, #PK-6100). The primary antibody against SULF2 (Novus 
Biologicals; same as used in Western Blot) was used at dilution 1:250 and 
incubated overnight at 4 °C.  Antibody binding was visualised by 3,3’-
Diamonobenzidine (DAB), (Vector Laboratories, #SK-4100) and cell nuclei 
counterstained with Mayer’s haematoxylin. Negative control included the 
omission of the primary antibody. 
Samples were also classified for the following parameters, age at diagnosis, 
clinical stage, MYCN status, mitosis-karhyorrhexis index (MKI), DNA index, 
degree of neuroblastic differentiation and favourable vs. unfavourable histology 
group according to the international Neuroblastoma Pathology Classification 
[Shimada et al., 1984; Shimada et al., 1999] and overall and event-free survival 
(EFS). Unfavourable histology (UH) tumours were either MYCN amplified (A) or 
MYCN non-amplified (NA) whereas all tumours with favourable histology (FH) 
were MYCN NA amplified. 
 
 41 
2.5.1 Microscopic evaluation of Sulf2 in primary NBL tissue 
Light microscope (Zeiss Axioplan) was used to take images (objective lenses 
magnification of 4 x, 10 x and 20 x and 63 x). Brown DAB reaction was 
considered positive for SULF2. A minimum of ten representative fields from 
each tissue section (central and peripheral tumour area) were photographed 
digitally using a Zeiss AxioObserver.Z1 microscope equipped with 20 x0.8 and 
63 x1.4 Plan-APOCHROMAT objective lenses and an AxioCam MR colour 
CCD camera (Carl Zeiss Microscopy). Files were saved in TIFF format (1600 x 
1200 pixels). 
 
2.5.2 Digital Image Analysis 
DAB staining in the 20x digital images was quantified using Fiji ImageJ software 
[Schindelin et al., 2012] in the following manner. Brown DAB and blue 
hematoxylin staining were separated into different images with the Color 
Deconvolution function using the H DAB matrix. The DAB image was then 
thresholded at 0-100 to include only the darkest pixels; staining lighter than 100 
intensity units was considered non-specific background and disregarded in the 
quantitation. The integrated density (ID) and area (A) of thresholded pixels were 
quantified and optical density (OD) was calculated with the formula OD = log 
[IDmax÷ (ID + IDmax – 255 × A)], where IDmax = 255 × 1388 ×1040, the 
maximum possible ID for an 8-bit image of 1388 × 1040 pixels. The samples 
were also classified for MYCN amplification and risk (high vs. low), according to 
the International Neuroblastoma Pathology Classification [Shimada et al., 
1999]. 
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2.5.3 Statistical Calculation of Required Tissue Samples and Analysis  
Preliminary data indicated that the estimated within group standard deviation of 
log10OD values for SULF2 expression by IHC is 0.138.  (The log10 scale is used 
to stabilize the variance) The average difference observed between these three 
groups in preliminary analyses was 0.24 on the log10 scale.  This corresponds 
to just under a halving or doubling of geometric mean OD between any two 
groups, and is a reasonable benchmark for sample size computation.  Based 
on a one-way, three group (A-UH, NA-UH, NA-FH) ANOVA with 10 samples 
per group, and with Type I error of 5 %, there will be at least 90 % power to 
detect a maximum difference of 0.24 between and two groups.  Other analyses 
in the one-way or two-way ANOVA setting of SULF2 expression by disease 
stage, age, metastatic disease, and other features of the tumour or patient will 
have similar power provided that there is reasonable balance among 
subgroups.  For example, a comparison two groups (e.g., metastatic vs. non-
metastatic disease) with a sample allocation of 1:3 will have at least 90% power 
to detect a 0.20 log10change in OD.  Hence it was accepted that there would be 
sufficient power to detect plausible and potentially relevant differences in 
SULF2 expression. Slides were then requested from the COG Committee from 
30 patients with NBL (10 for each group: A-UH, NA-UH and NA-FH).  
 
2.6 Transfection of Neuroblastoma cells 
Either small interfering RNA (siRNA) or short hairpin RNA (shRNA) was used to 
knockdown the expression of SULF2. For SULF2 over-expression the vector 
pcDNA3.1(-) was used. 
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2.6.1 Small interfering RNA (siRNA) of SULF2 in neuroblastoma cells 
Cells were seeded in cell culture plate and grown overnight to obtain 60-70% 
confluence at the time of transfection. Transfections of siRNA were performed 
in OptiMEM medium in the presence of 7.5 μl Lipofectamine RNAiMAX 
(Invitrogen, #13778-075) and a final siRNA concentration of 10nM siRNA 
oligonucleotides (siRNA#1 fwd GGUGCUACAUCCUAGAGAA, siRNA#1 rev 
UUCUCUAGGAUGUAGCACC, siRNA#2 fwd GGACAACACGUACAUCGUA 
and siRNA#2 rev UACGAUGUACGUGUUGUCC) were obtained from Life 
Technologies (Silencer Select for SULF2, #4392420, s31805 and s31806 and 
negative control #AM4611).  
 
2.6.2 SULF2 overexpression in neuroblastoma cells 
Two human SULF2 overexpressing constructs, a full length SULF2 [Addgene, 
plasmid #13004: pcDNA3.1/Myc-His(-)-HSULF2] and a catalytically inactive 
SULF2 (S2ΔCC)form with a mutation that changed cysteine 88 to alanine 
[Addgene, plasmid #13006 pcDNA3.1/Myc-His(-)-HSULF2 deltaCC] were used. 
Plasmid DNA was extracted (Qiagen, Plasmid Maxi kit, #12162) and DNA 
subcloning was performed by restriction enzyme digest technique. Cutting was 
done at cloning sites with XhoI and HindIII. Digested DNA was run on a 0.8 % 
agarose gel and the insert and vector band was cut out of the gel and purified 
(Qiagen, QIAquick Gel Extraction Kit, #28704). Insert was ligated into the 
pcDNA3.1(-) vector (Invitrogen #V795-20) using T4 DNA ligase enzyme (New 
England Biolabs #) in a 1:3 vector : insert molar ratio. Subcloned DNA was 
transformed into chemically competent E. coli (Invitrogen, One Shot TOP10 
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Chemically Competent E. coli, #C4040-10). Reaction was plated on LB agarose 
plates with 100μg ampicillin followed by selection of single colonies. DNA was 
extracted (Qiagen, Plasmid Mini Kit, #12123) and analysed by sequencing 
using T7 primer (Genewiz, San Diego, USA). Cells were grown in antibiotic free 
IMDM medium for 24 hours prior to plasmid DNA transfection.  Transfection 
was performed when cells were ~80 % confluent. For 6-well dishes plasmid 
DNA (2.5 μg) and Opti-MEM (250 μl) were mixed together and Lipofectamine 
2000 (Invitrogen, #11668-019) (10 μl) and Opti-MEM (250 μl) were mixed 
together for 5 min at RT. The diluted plasmid DNA and the diluted 
Lipofectamine 2000 were mixed together for a further 10 min at RT to allow the 
formation of DNA-Lipofectamine complexes. Complexes were added to cultured 
cells, which were used in experiments following 48 h incubation. For control 
cells the equivalent amount of empty pcDNA3.1/(-) was added in place of 
plasmid DNA. Neomycin was used for selection. 
2.6.3 SULF2 short-hairpin RNA (shRNA) construct and subcloning by restriction 
enzyme digest  
When using shRNA to knockdown SULF2, we observed that within 7-10 days 
SULF2 positive cells outgrew the SULF2-knockdown cells (shown by a 
decreased ratio of EGFP-positive to total cells). This limited the time available 
for in-vivo experiments. To avoid this, we aimed to use a tet regulated vector to 
allow control of the gene expression of SULF2. For shRNA we used two 
previously publishes target regions of SULF2 GGAGTGGTGGTGTCAATAA 
(1143) and GCTGAAGCTGCATAAGTGC (1413) and 
AACAGTCGCGTTTGCGACTGG as a control (scramble) [Nawroth et al., 2007].  
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First, we used the pLVTHM empty backbone (Addgene plasmid#12247) (Figure 
2.1) to insert the SULF2 oligonucleotides with the appropriate enzyme 
restriction site (iRNAi program for Mac, The Netherlands Cancer Institute, 
Amsterdam, The Netherlands), (Table 2.3). Second, the inserted sequences 
were then subcloned into a tet-inducible shRNA lentiviral vectors pLVCT-tTR-
KRAB (Addgene plasmid #11643) containing a GFP reporter gene and tet- 
inducible H1 promoter (Figure 2.2). 
Oligonucleotides were resuspended at a concentration of 2μg in a total volume 
of 50μl annealing buffer (10mN Tris, pH7.5, 50mM NaCl, 1m EDTA) and 
annealed in a PCR thermocycler (starting at 95°C for 2 minutes then gradually 
cooled to 25°C over 45 minutes). The empty vector was cut at the ClaI site and 
the annealed oligonucleotides were inserted by ligation (T4 ligase, #T0202; 
New England BioLabs Inc., USA) at an oligonucleotide to vector ratio of 3:1 
(Figure 2.3). Reactions were then transformed in One Shot® TOP 10 
chemically competent E. Coli cells (Invitrogen, #C4040-10), following the 
manufacture’s instructions. The bacteria were then grown on LB agar plates 
containing 100 μg/mL ampicillin at 37°C overnight. Single colonies were 
isolated from stab cultures and grown in LB broth with 100 μg/mL ampicillin for 
∼16 hours in a 37°C shaking incubator. Stocks were made for long-term storage 
in 50 % (v/v) glycerol and kept at -80°C. Plasmid DNA was prepared using 
commercially available kits (Qiagen, Mini Prep Kit #27104 and/or EndoFree 
Plasmid Maxi Kit #12362). Plasmid deposition was verified by sequencing 
(GENEWIZ) using the human H1 promoter forward primer 
TCGCTATGTGTTCTGGGAAA and/or SP6 forward primers 
 46 
ATTTAGGTGACACTATAG. PCR with H1 and SP6 was also employed to 
check the insert into the vector (Annealing Temp 50°C) and run on a 1 % (w/v) 
agarose gel. Additionally, DNA samples were sent for sequencing analysis 
using the H1 primer (GeneWiz, San Diego, CA; USA). Confirmed sequences 
were then used to subclone into the pLVCT-tTR-KRAB vector (Figure 2.3). 
The empty pLVCT-tTR-KRAB vector and the pLVTHM vector with the inserted 
SULF2 sequences were digested with restrictions enzymes FspI (#R0135, New 
England BioLabs) and MscI (#R0534 New England BioLabs) following the 
manufacture’s instructions and run on a 1 % (w/v) agarose gel (Figure 2.3).  
Desired bands of recipient plasmid and donor vector were cut and DNA 
recovered (QIAquick Gel Extraction Kit #28704; Qiagen). DNA ligation, 
transformation and colonies isolation were performed as above. Antarctic 
phosphatase (#M0289, New England BioLabs) was used after each ligation. 
The empty donor LVT-tTR-KRAB vector (after digestion with FspI and MscI and 
separated on agarose gel) that was without the AmpR-promoter region was 
used as a control on the LB plates (no growth). Sequencing (GeneWiz) was 
used to confirm accurate subcloning using the H1 primer.  
SULF2 
1143 S 
5’ – CGCATCGATCCCCGCTGAAGCTGCATAAGTGCTTCAAGAGAGCACTTATGCAGCTTCAGCTTTTTAATCGATCGC 
SULF2-
1143 AS 
5'- GCGATCGATTAAAAAGCTGAAGCTGCATAAGTGCTCTCTTGAAGCACTTATGCAGCTTCAGCGGGGATCGATGCG 
SULF2 
1413 S 
5’- CGCATCGATCCCCGGAGTGGTGGTGTCAATAATTCAAGAGATTATTGACACCACCACTCCTTTTTAATCGATCGC 
SULF2 
1413 AS 
5' – GCGATCGATTAAAAAGGAGTGGTGGTGTCAATAATCTCTTGAATTATTGACACCACCACTCCGGGGATCGATGCG 
SULF2 
Scr S 
5’- 
CGCATCGATCCCCAACAGTCGCGTTTGCGACTGGTTCAAGAGACCAGTCGCAAACGCGACTGTTTTTTAATCGATCGC 
SULF2 
Scr AS 
5'- 
GCGATCGATTAAAAAACAGTCGCGTTTGCGACTGGTCTCTTGAACCAGTCGCAAACGCGACTGTTGGGGATCGATGCG 
Table 2.3 SULF2 shRNA oligonucleotides with restriction sites. ClaI restriction site 
are highlighted in red, vector loop is shown in blue. SULF2 sequences are in bold. 
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Figure 2.1 pLVTHM vector. The ClaI site (red dashed line) was used to insert the 
SULF2 oligonucleotides.  
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Figure 2.2 Subcloning from the pLVTHM vector by restriction enzyme digestion. 
The pLVTHM vector containing the SULF2 sequence inserted at ClaI site is cut out at 
FspI and MscI sites (orange dashed line) to allow ligation into the new vector (Figure 
2.2). 
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Figure 2.3 Subcloning into pLVCT-tTR-KRAB vector. The recipient pLVCT-tTR-
KRAB vector is digested with the enzymes MscI and FspI (empty vector marked in 
yellow on agarose gel – top left image) to allow insertion of the SULF2 sequence cut 
out from the pLVTHM vector (orange circle on agarose gel – top left image).  
 
 
2.6.4 Lentivirus production 
For transfection 2.5 x 106 293T cells (ATCC #11268) were seeded into each 
10-cm cell culture dish and grown overnight to reach ∼60-70 % confluence. Ten 
μg of the transfer vector plasmid pLVTHM, 2 μg of the envelope plasmid 
pMD2.G (Addgene, Plasmid #12259) and 2 μg of packaging plasmid 
pCMVR8.74 (Addgene, Plasmid #22036) were mixed with 2.5 M CaCl2 and 
HBS (pH 7.12) and added to each 10-cm dish. The following day cells were 
washed with Dulbecco’s PBS (DPBS) and incubated with DMEM medium 
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supplemented with 10mM sodium butyrate and 20mM HEPES for 18 h. Cells 
were then washed with DPBS and incubated with DMEM containing 20mM 
HEPES for further 48 h. The viral supernatant was removed and filtered through 
a 0.45 μm vacuum filter and ultracentrifuged at 26.000 rpm for 90 min at 4 °C. 
The pellet was resuspended in DPBS and stored at -80°C. NBL cells were 
grown in a 12-well plate to ∼50 % confluency and transfected with the produced 
shRNA SULF2 regions 1144, 1413 and the scramble. Successfully transfected 
cells (5 x 106 cells) were sorted by FACS 3 days after transfection.  
 
2.7 Cell viability assays 
Crystal violet was used for cell viability. Cells were grown and transfected with 
siRNA as described above in 96-well flat-bottomed micro titer plate. After 48 h 
cells were then fixed with 4 % (w/v) paraformaldehyde and subsequently, 
stained with 1 % (w/v) crystal violet for 30 min and then rinsed with PBS. Cells 
were also grown in 96-well plates (2x104 cells /well) and transfected with 
siRNAas described above. CellTiter-Glo Luminescent cell viability assay 
(Promega #G7570) was used following the manufacturer’s instructions.  
 
2.8 Apoptosis 
For apoptosis assays, cells were grown in a 96-well plate in a final 50 μl volume 
under the same conditions and analysed for caspase 3/7 activity (ApoLive-Glo 
Multiplex Assay; Promega #G6410). For Annexin V assessment, cells were 
grown in 6-well plates (4x105 cells/well) and Annexin V and propidium iodide 
staining (PI) was done in accordance to manufacturer’s instructions (FITC 
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Annexin V Apoptosis Detection kit, BD Biosciences #556547). FACS scan flow 
cytometer was used with the CellQuestPro software. Western blotting was used 
to assess caspase-3 and PARP cleavage (see 2.3 Western Blotting). 
 
2.9 Cell cycle analysis 
Cell cycle analysis was performed using BrdUincorporation (FITC BrdU Flow 
kit, BD Pharmingen #552598). Annexin V and BrdU were analysed on a 
Beckman FACScan flow cytometer using CellQuestPro software. 
 
2.10 Statistical analysis and graphs 
All numerical data were calculated as means ± standard deviations (SD) or 
standard errors of the mean (SEM). Differences between groups were 
compared using Student’s t- test (ANOVA). Statistical analysis for the gene 
expression microarray data was performed with R Project Software (version 
3.0.1) with one-way ANOVA followed by Wald’s test for comparing differences 
between multiple groups and correcting for multiple testing when appropriate. 
Differences were considered significant at p < 0.05. Graphs were created using 
GraphPad Prism 6 Software. 
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Chapter 3: SULF2 expression in MYCN amplified neuroblastoma 
 
3.1 Introduction 
HSPGs have an essential role in the interaction between cancer cells and the 
tumour microenvironment (TME) and are involved in many processes including 
cell proliferation, adhesion, migration and invasion [Esko and Lindahl, 2002; 
Esko and Selleck, 2002; Iozzo, 2005; Sasisekharan et al., 2002]. Their function 
has largely been attributed to sulfation motifs in HS chains that are controlled 
by regulatory enzymes such as biosynthetic sulfotransferases that add sulfate 
groups, and by extracellular sulfatases that selectively remove 6-O-sulfates 
[Vives et al., 2014]. Sulfate groups modulate the binding and interaction of HS 
with several growth and signaling factors.  
The increasingly reported importance of sulfatase enzymes such as the SULFs 
to cancer cells and their microenvironment has led us to question their role in 
NBL. Early work in the 1980’s analysed the biochemical composition of HSPGs 
of NBL cells in vitro identifying distinct HS populations from cells and from the 
medium [Maresh et al., 1984; Hampson et al., 1983; Hampson et al., 1984]. 
Recent evidence showed that children with solid tumours and with NBL have 
high levels of heparanase, the endoglycosidase enzyme that cleaves HS chains 
into large oligosaccharide fragments, and that this correlates with responses to 
treatment [Zheng et al., 2009; Shafat et al., 2007]. HS remains an under-
researched, but vital “missing link” in enabling proteins to be regulated to 
support or suppress cancer growth and development. A comprehensive 
analysis on the expression of HSPGs in NBL has not been carried out to date. 
Here, in Chapter 3, the expression of HS and some of its biosynthetic and 
modification enzymes in NBL cell lines are investigated.  
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3.2 Hypothesis and Aims 
The hypothesis of this chapter was that human NBL have a distinct HS 
molecular phenotype that may be associated with tumour behaviour. 
To test the above hypothesis the specific aims of this chapter were: 
• To examine the expression of key enzymes that control the sulfation 
patters of HS in human NBL and other cell lines  
• To characterize the expression of HS in NBL cell lines 
• To identify gene expression changes in HS enzymes that may be linked 
to specific NBL characteristics 
 
3.3 Results 
3.3.1 Expression of heparan sulfate biosynthetic and modification enzymes 
in cell lines 
To test the hypothesis, the gene expression of several enzymes that regulate 
the sulfation of HS was analysed by RT-PCR technology. Overall, 8 NBL cancer 
cell lines were studied (CHLA-255, CHLA-90, SK-N-SH and SK-N-RA, CHLA-
136, SK-N-BE2, SMS-SAN and NB-19); (Table 1.2). In order to evaluate 
whether any changes in gene expression were relevant to neuroblastoma, 
changes in HS biosynthetic enzyme expression was also checked in other 6 
cancerous non-NBL cell lines (A-549 lung carcinoma, MG-63 osteosarcoma, 
HT-1080 fibrosarcoma, HeLa cervical cancer, MDA-MB-231 breast cancer and 
C-8161 melanoma) and non-cancerous human cell lines (human brain 
microvascular endothelial cells - HBMEC and human fibroblasts). The rationale 
behind this experiment was that a significant difference in expression (up- or 
down-regulation) between neuroblastoma cell lines (or a subgroup of cell lines) 
and the other cell lines, would identify enzyme(s) with a role in neuroblastoma 
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pathogenesis. Genes were selected (Table 3.1) with a focus on 2 major families 
of biosynthetic enzymes, the HS O-sulfotransferases (OSTs) and the N-
deacetylase/N-sulforansferases (NDSTs) that increase sulfation of HS chains 
during their biosynthesis, and on the SULFs that remove 6-O-sulfate from 
glucosamine residues of HS extracellularly. The gene expression analysis was 
very informative as it revealed the most highly expression of SULF2 mRNA in 
the neuroblastoma cell lines (Figure 3.1). Particularly, mRNA for this enzyme 
was more abundantly expressed (-ΔCT >15) in 4 neuroblastoma cell lines 
(CHLA-136, SK-N-BE(2), SMS-SAN and NB-19) when compared to the other 
cell lines (Figure 3.1 and Figure 3.2). All the neuroblastoma cell lines that had 
the high levels of SULF2 were MYCN-A. The significantly lower levels of SULF2 
mRNA in the MYCN-NA neuroblastoma cell lines expressed were comparable 
to the levels of the other non-neuroblastoma cell lines (p<0.01). Interestingly, 
the melanoma cell line C8161 (also a neuronal crest derived tumour like 
neuroblastoma) showed significantly elevated expression of SULF2. Overall, 
the relative expression of SULF1 mRNA was not significantly different amongst 
the MYCN-A and MYCN-NA neuroblastoma cell lines (p=0.15). When 
comparing the MYCN-A and MYCN-NA neuroblastoma cells, no significant 
changes in expression were observed uniquely in all lines for 2OST1, 3OST1, 
6OST1 and 6OST2. 6OST3 had low levels of expression on 2 out of 4 MYCN-A 
neuroblastoma cell lines (SK-N-BE(2) and SMS-SAN)  when compared to the 
MYCN-NA (SK-N-SH and SK-N-RA). The highest 6OST3 mRNA expression 
was present in the melanoma cell line C8161 (Figure 3.2). The expression of all 
NDSTs was also unaltered among the neuroblastoma cell lines; with the lowest 
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levels for the isoform NDST4 (Figure 3.1). NDST3 had the lowest levels in the 
non-neuroblastoma cell lines (Figure 3.2).  
These findings showed that SULF2 mRNA was significantly increased in 
neuroblastoma cell lines when MYCN was amplified. Interest was then focused 
on SULF2 in neuroblastoma.  
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Figure 3.1 mRNA expression of sulfation modifying enzymes in neuroblastoma 
cell lines measured by qRT-PCR. cDNA from neuroblastoma cells was obtained by 
reverse transcription. The amount of RNA for each enzyme was determined by qRT-
PCR as described in Materials and Methods. The data represent the negative mean 
ΔCT ± S.E.M. [-(value of gene – control value of GAPHD)] from 3 aliquots of samples 
obtained each from 3 separate experiments. Higher -ΔCT expression values represent 
higher level of expression. Statistical significance was determined using Student’s t-
test (* indicates p< 0.05). MYCN-NA = non amplified; MYCN-A = amplified. See Table 
2.2 for oligonucleotides/gene information. 
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Figure 3.2 mRNA expression of sulfation modifying enzymes in non-
neuroblastoma cell lines measured by qRT-PCR. See Table 2.2 for 
oligonucleotides/gene information. 
 
To further assess the expression of the HS biosynthetic enzymes in NBL, the 
qRT-PCR findings were validated at the protein level by Western blot analysis. 
This study confirmed that SULF2 protein was abundantly present in the cell 
lysate of the four neuroblastoma cell lines with MYCN amplification when 
compared to the four MYCN-NA cell lines in which the MYCN protein was 
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absent or expressed at very low levels (Figure 3.3). The 125-kDa component in 
the detergent lysate corresponds to the unprocessed pre-protein of SULF2 
[Morimoto-Tomita et al., 2002]. Additionally, the processed form is expressed 
(data not shown), in keeping with the reports in the literature [Lemjabbar-Alaoui 
et al., 2010]. However it is not well known what functional differences the 
processed and unprocessed forms may exhibit, but dominant negative effects 
of the unprocessed forms cannot be excluded. 
 
 
Figure 3.3 SULF2 is specifically overexpressed in MYCN-A neuroblastoma cell 
lines. Western blot analysis of SULF2 in 8 neuroblastoma cell lines was performed as 
indicated in Materials and Methods. From left, lanes 1-4 are MYCN-NA cell lines and 
lanes 5-8 are MYCN-A cell lines. 
 
 
 
 
 
3.3.2 Neuroblastoma cells have distinct sulfated heparan sulfate epitopes  
To examine the expression of HS on the surface on NBL cell lines, the 10E4 
antibody was used; this is a mouse anti-human HS antibody that targets 
common HS epitopes containing extended N-sulfated domains, possibly also 
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mixed with NAc sequences [David et al., 1992; van den Born et al., 2005]. 10E4 
was localized homogenously on cell surface of all NBL cells with slightly higher 
expression in the MYCN A cell lines SKNBE(2) and SMS-SAN (MYCN A), 
(panel iii and iv, Figure 3.4) when compared to the MYCN NA cell lines CHLA-
255 and CHLA-90, (panel i and ii, Figure 3.4). The 10E4 antibody reacts with an 
epitope that is present in native HS chains and consist of mixed N-sulfated and 
N-acetylated heparan sulfate [van den Born et al., 2005]. There are no reported 
colocalisation studies with 10E4 and SULF2 and we did not double stain the 
NBL cells as both have the same source (raised in mouse). It is unclear why an 
elevated SULF2 levels might correlate with an increased levels of HS by the 
10E4 antibody. 
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Figure 3.4 Immunocytochemistry to detect heparan sulfate in NBL cell lines. 
Panels i to vi were stained with an anti-HS antibody (10E4). Panels i-ii represent 
MYCN non-amplified NBL cell lines, panels iii-vi are MYCN amplified cell lines. DAPI 
was used to stain cell nuclei (blue). Scale bars are 20 μm. 
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Figure 3.5 SULF2 (red) and HSPG (green) in neuroblastoma cells in culture by 
immunofluorescence. Panels on the left represent MYCN-NA cells, whereas panels 
on the right are MYCN-A cells. Panels i and ii were stained with an anti-HSPG antibody 
(HS3B7V). Panels iii to vi were double stained with an anti-HSPG phage display 
antibody (HS3B7V) that specifically recognizes highly 6-O-sulfated epitopes (green) 
and with an anti-SULF2 antibody (red). DAPI was used to stain cell nuclei (blue). Scale 
bars are 20 μm. 
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To determine whether over-expression of SULF2 in neuroblastoma cells was 
affecting the sulfation pattern of HSPG, immunocytofluorescence studies were 
conducted using an antibody against SULF2 and phage display antibodies 
against HSPG (Figure 3.5). We then used a panel of phage display antibodies. 
The phage display antibody HS3B7V recognised the presence of similar levels 
of IdoUA-GlcNS6S containing domains at the cell surface of both MYCN-A and 
MYCN-NA cell lines (Figure 3.5, panel i and ii). The phage display antibody 
HS3A8V that recognizes highly sulfated domains within HS that depend on 6-
O-, N-sulfated glucosamine (GlcNS6S) and sulfated iduronic acid (IdoUA2S) 
over non-sulfated iduronic acid (IdoUA), [Dennissen et al., 2002] with the 
preferred sequence GlcNS6S-IdoUA2S-GlcNS6S, was then employed. These 
epitopes are potential substrates for SULF2 [Ai et al., 2003] and are typical 
components of HS but, are not present at high levels. Using 
immunocytochemistry staining on fixed NBL cells, the level of HS3A8V was 
significantly lower in MYCN-A cell lines, which expressed high levels of SULF2 
(Figure 3.5, panels iii to vi). No staining was seen in the absence of primary 
antibody (Figure 3.6). The data indicated that among the enzymes controlling 
the pattern of sulfation of HSPG, SULF2 was the only one that was clearly 
differentially expressed in MYCN-A cell lines when compared to all other cell 
lines. SULF2 and HS stained by the phage display antibodies did not show any 
co-localisation. They also consistently demonstrated that the presence of higher 
levels of SULF2 was associated with a significant decrease in the level of 
sulfation of HSPG in these cells. These correlative data suggested a potentially 
important role of SULF2 in the pathogenesis of MYCN-A driven neuroblastoma. 
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Figure 3.6 Confocal microscopy of negative controls for immunofluorescence 
staining. Endogenous heparan sulfate was digested with heparitinase and then 
stained with phage-display antibody HS3A8V using Alexa-fluor-488 (i). As a second 
control, omission of the primary antibody anti-SULF2 (2B4) was used and stained with 
Alexafluor-594 (ii). DAPI staining (blue) reveals the nuclei. Scale bars are 20 μm.  
 
3.4 Discussion 
 
The main findings of this Chapter were 1) SULF2 is high in NBL cell lines when 
compared to other cell lines and particularly when MYCN is amplified (A); 2) 
NBL cell lines that are MYCN-A have decreased expression of 6-O sulfation 
epitopes on their surface. 
This is the first comprehensive analysis of the expression patterns of HSPGs 
and their modifying enzymes in human NBL.  
Here we observed, first, that SULF2 is highly expressed in a series of 
NBL cell lines when MYCN is amplified. Our experiments started by screening 
16 cell lines (8 NBL and 8 cancer and normal cell lines) for several HS 
biosynthetic enzymes that regulate HS sulfation and found that SULF2 was 
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highly expressed in NBL cell lines in which MYCN is amplified when compared 
to other cell lines. The same cell lines also had abundant protein levels of 
SULF2 by WB analysis. SULF1 was present in all NBL cell lines examined but 
was always lower than the levels of SULF2 and showed no significant 
differences amongst the cell lines. It has frequently been reported in the 
literature that SULF1 and SULF2 are not always expressed in cancer cell lines. 
For example in non-small cell lung carcinoma (NSCLC) [Lemmjabbar-Alaoui et 
al., 2010] showed that of a total of 18 cell lines, all of which are tumorigenic in 
immunocompromised mice, SULF2 was present in seven and SULF1 in three, 
while the remaining eight did not express either. Nawroth et al. reported that 
SULF1 is expressed in 15/24 and SULF2 in 23/24 human pancreatic 
adenocarcinoma cell lines [Nawroth et al., 2007]. We found that both SULFs 
mRNAs are expressed amongst all 16 cell lines tested. The differences in the 
results may be due to the more efficient gene expression analysis we used in 
our experiments with a much more sensitive detection by real-time qPCR, 
compared to standard RT-PCR and gel electrophoresis. Our gene expression 
data showed that the melanoma cell line C8161 had very high levels of SULF2 
similarly to the NBL with MYCN A. This is of interest as melanoma is also a 
neural crest derived tumour like NBL and high expression levels of SULF2 were 
identified in tissue from patients with high-grade uveal melanoma when 
compared to low grade [Bret et al., 2011]. In the study by Iwao K et al [Iwao et 
al., 2009] it was demonstrated that HS regulates optical and cranial neural crest 
development through TGF-β2 signaling; the disruption of HS caused several 
developmental facial and eye abnormalities. Similarly, in Xenopus tropicalis, 
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neural crest migration required SULFs (SULF1 and SULF2); when the SULFs 
were ectopically expressed in the environment, there was a disruption of neural 
crest cell migration [Guiral et al., 2010]. This showed that SULFs and especially 
SULF2 play a role in neural crest migration and therefore possibly in NBL 
development. In our study, the SULF2 overexpression was also shown at the 
protein level in the same NBL cell lines and correlated with the gene expression 
profiles. To the best of our knowledge no study in the literature analysed a 
colocalisation of SULF2 and MYCN during development. This might be of 
interest in neural crest development where both factors are reported to be 
essential [Guiral et al., 2010; Schwab, 2004; Soucek et al., 2008; Arvanitis and 
Felsher, 2006]. SULF2 is present on the cell surface and is secreted into the 
ECM by cancer cells, where it regulates elements of oncogenesis [Phillips et 
al., 2012] and it can probably be produced also by other cell types such as the 
cancerous stroma [Phillips et al., 2012; Bret et al., 2011]. The secreted SULF2 
might have deleterious non-autonomous effects that alter the tissue 
microenvironment influencing cellular phenotype. To date, a comprehensive 
analysis of the secreted sulfatases in cancer is lacking.    
Second, it is thought that levels of 6-O sulfation are inversely related to 
SULF2 expression.  Immunocytochemistry and FACS analysis with phage 
display antibodies showed that overall 6-O sulfation is not elevated in NBL cells 
where SULF2 is highly expressed on cell surface. This finding is in agreement 
with reported data in the literature where cells with high levels of SULF2 have 
low levels of 6-O sulfation [Phillips et al., 2012; Lemmjabbar-Alaoui et al., 
2010], showing that the enzymes function depends on its activity as a 
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endosulfatase of HSPGs. Similarly in our preliminary experiments (See 
Appendix 1) 6-O sulfation was increased in the two MYCN NA NBL cell lines 
(SHEP and SHSY5Y) that express very low levels of SULF2. In the same way, 
the NBL cells studied by Hampson et al., with high levels of 6-O sufation might 
have been MYCN NA [Hampson et al., 1983; Hampson et al., 1984]. 
The HS3A8V antibody reacts with trisulfated disaccharide motifs of HS 
[Dennissen et al., 2002] and because it is less abundant on the cell surface of 
NBL cells that have high SULF2 levels, it can be assumed that SULF2 
remodels the sulfation profile of HS locally.  
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Chapter 4: The effects of SULF2 alteration on neuroblastoma cell lines 
 
4.1 Introduction 
NBL is an aggressive childhood cancer that accounts for 10 % of all childhood 
cancers and for approximately 15 % of all cancer deaths in children [Maris and 
Matthay, 1999]. High-risk NBL tumours with MYCN amplification (A) still have a 
high mortality rate despite multimodal therapies and new therapies that are 
effective against multidrug resistant NBL are needed. 
In Chapter 3 increased SULF2 levels were observed in high-risk NBL cell lines 
when MYCN was amplified and associated with a decrease in 6-O-sulfation on 
cell surface HS. Recently it has been shown that SULF2 was overexpressed in 
a series of human cancers [Lui et al, 2012; Bret et al., 2011] and it has been 
directly implicated in driving tumourgenesis in human glioma and non-small 
lung carcinoma. Here it was associated with low levels of 6O-sulfation [Phillips 
et al., 2012; Lemjabbar-Alaoui et al., 2010]. Furthermore the reduction of 
SULF2 expression decreased the growth of gliomas and decreased the activity 
of PFGFRalpha and downstream signalling pathways [Phillips et al., 2012]. 
Similarly, in non-small cell lung carcinoma the down regulation of SULF2 
induced cell death and apoptosis [Lemjabbar-Alaoui et al., 2010]. 
Overexpression of SULF2 promoted carcinogenesis in the lung [Lemjabbar-
Alaoui et al., 2010]. Several methods were used to test the effects of SULF2 
alterations by siRNA on apoptosis and viability. We measured the proliferation 
after SULF2 KD in two NBL cell lines with MYCN A using two assays. First, we 
used the CellTiterGLow (CTG) luminescence assay, which indirectly measures 
the number of viable cell by quantifying the amount of ATP present in a 
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metabolically active cell while concurrently inhibiting ATPases.  This assay has 
been shown to be sensitive and give a stable luminescent output. Second, we 
used a classic fluorescent BrdU incorporation with cell cycle analysis by FACS 
with 7-AAD allowing the enumeration and characterisation of cells that are 
actively synthesising DNA (BrDU incorporation) in term of other cell cycle 
positions defined by 7-AAD staining.  
In this chapter we focus on measuring the effects of loss of SULF2 on 
apoptosis.  Apoptosis is the most common form of programmed cell death and 
since many features overlap among different forms of cell death we used 
various techniques. Caspases are cysteine-dependent aspartate-specific 
proteases involved in the execution of both intrinsic and extrinsic apoptosis 
[Lakhani et al., 2006.] Caspase-3 is one of the most effective caspases 
[Lakhani et al., 2006] and the proenzyme is activated by cleavage, which allows 
the formation of two dimerised and active subunits. Cleaved caspase-3 also 
cleaves and activates caspase-7; both have some overlapping roles that are 
common to the intrinsic and extrinsic apoptotic pathways [Lakhani et al., 2006]. 
Casapse-3 controls DNA fragmentation, whereas caspase-7 is more important 
for loss of cell viability [Lakhani et al., 2006]. PARP is cleaved by caspase-3 
and 7 and is involved in DNA repair, differentiation and chromatin structure 
formation [Germain et al., 1999].  Caspase-3 and 7 activation is an indication 
that apoptosis will initiate whereas PARP activation is an indication that the cell 
is actually undergoing apoptosis. Additionally we analysed caspase-3 and 
PARP cleavage (89 kDa fragment containing the catalytic domain) by western 
blotting.   
 69 
We use siRNA technology to knockdown SULF2 expression, using a previously 
reported SULF2 overexpression transfection [Lemjabbar-Alaoui et al., 2010] 
and SHEP cells with the tet21N system, which express MYCN in the presence 
of tetracycline [Lutz et al., 1996].  
Here in Chapter 4 we focus on the effects of SULF2 on growth and apoptosis in 
NBL cell lines. We also study the correlation of SULF2 to MYCN and provide 
evidence for a downstream target.  
 
4.2 Hypothesis and Aims 
In Chapter 3 it has been shown that SULF2 is predominantly overexpressed 
in NBL cell lines are MYCN amplified. This raises the question whether:  
• SULF2 has a role in the survival of NBL cell lines that are MYCN 
amplified 
• MYCN amplification regulates SULF2 expression  
 
Therefore, the aims of this chapter were:  
• To examine the effects of SULF2 knockdown and overexpression on 
the survival of NBL cell lines in-vitro  
• To study the effects of MYCN alterations on SULF2 expression  
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4.3  Results 
4.3.1 Knockdown of SULF2 expression in MYCN amplified 
neuroblastoma cells results in loss of cell viability 
To evaluate whether increased SULF2 levels in neuroblastoma were of 
biological importance, the effects of down-regulation of SULF2 expression in 
MYCN-A neuroblastoma cell lines were analysed. Two MYCN-A cell lines with 
strong expression of SULF2 [SK-N-BE(2) and NB-19] were transfected with 
either specific SULF2 siRNA (SULF2 siRNA 1 or 2 and a combination of both), 
or with a control siRNA. Both siRNA transfected cell lines showed a marked 
reduction in the expression of SULF2 compared to the control cells (>85-90%) 
(Figure 4.1, A). The knockdown (KD) of SULF2 did not cause a reduction of the 
expression of MYCN in either cell line. The KD of SULF2 in these cells resulted 
in a significant reduction in cell density in culture when compared to scramble-
transfected controls as shown by crystal violet staining (Figure 4.1, B).  
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Figure 4.1 Knock down of SULF2 expression in neuroblastoma cells. 
Knock down of SULF2 results in loss of viability. MYCN-A SK-N-BE(2) and NB-19 
neuroblastoma cells were transfected with siRNA for SULF2 and examined for survival 
and proliferation as described in Materials and Methods. A, Western blot analysis of 
SULF2 expression on cell lysates obtained 48 hours after transfection with SULF2 
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siRNA and scrambled siRNA (scR). B, Representative crystal violet stains of cells in 
culture 48 hours after transfection. C, Cell viability was measured at the indicated time 
by the CellTiter-Glo luminescent cell viability assay as indicated in Materials and 
Methods. The data represent the mean (+/- SD) fluorescence units (RLU) of 
quadruplicate samples in 3 separate experiments (n=12); (* p < 0.05; ** p < 0.01; *** p 
< 0.0001). D, NB-19 cells were incubated with BrdU for 2 hours, harvested, 
permeabilised and stained with PI. The presence of BrdU and PI was then examined 
by flow cytometry. The data are representative of 2 experiments showing similar 
results. Top panel: Cells transfected with SCR; bottom panel: cells transfected with 
siRNA 1 + 2. E, Bar diagram of the distribution of cells in phases of cell cycle according 
to PI content from the experiments shown in D. 
 
It was then demonstrated that loss of SULF2 expression in these MYCN-A cells 
[SKNBE(2) and NB-19] resulted in a significant decrease in cell viability when 
compared to the control transfection (Figure 4.1, C and D). The data thus 
indicated that SULF2 is required for cell viability in MYCN-A neuroblastoma 
cells. To determine whether the presence of SULF2 stimulated cell proliferation, 
the effect of SULF2 KD on cell cycle and BrdU incorporation was examined in 
MYCN-A NB-19 cells. This analysis revealed a significant decrease in the 
percentage of BrdU positive cells in S phase from 25.5% to 18.4% (Figure 4.1, 
D). An analysis of the cell cycle distribution of the cells revealed a decrease in 
the percentage of cells in S phase and in G2 (from 9.5% to 4.4%) and an 
increase in the sub- G0 cell population (from 4% to 22%) suggesting that 
SULF2 is a requisite for cell cycle entry and may protect cells from apoptosis 
(Figure 4.1, E). We did not investigate the effects on cell proliferation and 
survival of MYCN overexpression as these are well reported in the literature 
[Lutz et al.,1996]. We also did not study the effects of SULF2 KO in MYCN NA 
NBL cell lines as these cells already had very low expression levels of SULF2.  
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4.3.2 SULF2 protects MYCN amplified neuroblastoma cells from 
apoptosis 
 
To test the hypothesis that SULF2 protects neuroblastoma cells from apoptosis, 
the level of caspase 3/7 was measured in cells in which SULF2 was knocked 
down by siRNA. Consistent with a protective effect of SULF2 on apoptosis, the 
data indicated an increase in caspase 3/7 activity upon SULF2 KD in SK-N-
BE(2) and NB-19 cells in 72 hours (Figure 4.2, A). The increase in apoptosis 
upon SULF2 KD was confirmed by Western blot analysis, which demonstrated 
an increase in cleaved poly ADP ribose polymerase (PARP) and cleaved 
caspase-3 in SULF2 siRNA transfected SKNBE(2) and NB-19 cell lines (Figure 
4.2, B). This corresponded to an increase in Annexin-V positive cells at 48 
hours in NB-19 cells (Figure 4.2, C). The data thus indicated that SULF2 plays 
an important role in the viability of MYCN-A neuroblastoma cells, not only by 
promoting cell proliferation but also by protecting cells from spontaneous 
apoptosis.  
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Figure 4.2 Loss of SULF2 expression induces apoptosis.  
(A) Caspase 3/7 activity in SULF2 siRNA transfected SK-N-BE(2) and NB-19 cells was 
measured using the ApoLive-Glo system as indicated in Materials and Methods. The 
data represent the mean (±SD) luminescence units (RUL) of triplicate sample from one 
experiment and are representative of 3 independent experiments showing similar 
results. (B) Western blot analysis of SK-N-BE(2) and NB-19 cells transfected with 
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SULF2 siRNA and a scramble control, and harvested 48 hours after transfection. (C) 
Apoptosis in cells transfected as indicated in A, was determined by flow cytometric 
analysis of Annexin V/PI staining in NB-19 cells transfected with SULF2 siRNA and 
scramble control. Values are mean ± S.E.M. of three independent experiments. *p < 
0.05. 
 
4.3.3 SULF2 is a possible down stream target of NMYC and promotes 
cell viability 
 
The correlation between MYCN and SULF2 expression in cell lines combined 
with the observation that loss of SULF2 expression decreases the viability of 
MYCN-A cells, suggested that SULF2 could be a downstream target of MYCN. 
To test this hypothesis, we wanted to examine the effects of SULF2 
overexpression in a NBL cell line that does not express (or have very low 
levels) of MYCN. For this purpose we used the cell line CHLA-255 as it has 
almost undetectable levels of SULF2 and was easy to transfect with the 
plasmid vector. For this experiment we used two constructs overexpressing 
SULF2, one containing the wild-type (WT) human SULF2 and another with an 
inactive mutant of SULF2 (pcDNA3.1ΔCC).  
Transfection of the cell line CHLA-255 with the overexpressing vectors resulted 
in an increase of SULF2 expression (Figure 4.3, A) in both the WT and an 
inactive SULF2 mutant. Induced SULF2 overexpression did not affect MYCN 
expression. This demonstrated that SULF2 might be downstream and not 
upstream of MYCN. Consistent with a protective role of SULF2 against 
apoptosis, we also demonstrated an increase in viability of SULF2-
overexpressing CHLA-255 cells over 4 days in culture but not of cells 
overexpressing the inactive mutant or of untransfected parent cells (Figure 4.3, 
B). 
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Figure 4.3. SULF2 is a target of MYCN and promotes cell viability.  
(A) CHLA-255 cells were stably transduced with MYCN cDNA, a SULF2 WT cDNA, a 
mutant inactive SULF2 (S2ΔCC) or an empty vector control and examined for SULF2 
and MYCN expression by Western blot analysis after 48 hours. β-actin was used as a 
loading control. (B) CHLA-255 cells transfected as indicated in (A) were cultured for 4 
days and examined for viability at the indicated time points as described in Figure 4.3 
C. The data represent the mean (±SD) luminescence units (RLU) of triplicate samples  
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(4 samples in 3 different experiments; n=12). (C) SHEP-21N cells were treated with 
tetracycline (Tet) at indicated time points (0-18 hours), and after 18 hours Tet was 
removed from the medium, and cells were kept in culture for another 24 hours. MYCN 
and SULF2 expression in cell lysates was examined by Western blot analysis at 
indicated times. (D) SHEP-2 cells were transduced with either SULF2 WT or an 
inactive mutant SULF2 (S2ΔCC) cDNA and examined for SULF2 and MYCN 
expression by Western blot analysis. (E) Cell viability was analysed by CellTiter-Glo 
over time. The data represent the mean (± S.E.M.) luminescence (RLU) of triplicate 
samples  (4 samples in 3 different experiments; n=12). *p<0.05; ***p<0.001. All 
experiments were conducted at least three times. 
 
4.3.4 MYCN regulates SULF2 expression in NBL cells  
 
We next investigated the effects of a stable transfection with MYCN in the NBL 
cell line CHLA-255 that normally does not express (or have minimally 
detectable levels of) MYCN [Song et al., 2007]. This analysis revealed that 
overexpression of MYCN in CHLA-255 cells was associated with a 
corresponding increase in SULF2 expression (Figure 4.3, A) indicating a direct 
link between MYCN and SULF2. This observation was confirmed using the 
neuroblastoma cell line SHEP-21N, a subclone of the cell line SHEP (which has 
barely detectable levels of MYCN and SULF2) transfected with a tetracycline 
regulated (tet-off) MYCN expression vector [Rossler et al., 2001]. In the 
absence of tetracycline, these cells stably express MYCN and also SULF2 
(Figure 4.3, C), which is consistent with our previous data.  
In contrast, treatment of SHEP-21N cells with tetracycline resulted in loss of 
MYCN protein expression after just 4 hours as anticipated and a progressive 
decrease in SULF2 protein at 12 and 18 hours. Removal of tetracycline resulted 
consistently in rapid re-expression of MYCN that was followed later (24 hours) 
by re-expression of SULF2. These data further demonstrated that SULF2 is a 
 78 
downstream target of MYCN. To confirm that SULF2 had no effect on MYCN 
expression, we overexpressed WT SULF2 or a loss of function mutant SULF2 
as control in MYCN-NA parent SHEP-2 cells. Neither of these experiments had 
an effect on MYCN expression (Figure 4.3, D), which is consistent with the 
results obtained from MYCN-NA CHLA-225 overexpressing SULF2. Importantly, 
overexpression of SULF2 in MYCN-NA SHEP cells increased cell survival 
demonstrating again that, although a target of MYCN, SULF2 stimulates 
neuroblastoma cell survival by an MYCN independent mechanism (Figure 4.3, 
E). Possible non-autonomous or paracrine effects of SULF overexpression are 
not explored in this thesis. To provide evidence that SULF2 is a downstream 
target of MYCN we also performed a CHIP assay to assess the promoter region 
of SULF2 to MYCN (see Appendix 2).  
 
4.4 Discussion 
In this chapter two novel observations that shed light on the important role that 
the pattern of sulfation of HSPG plays in MYCN-driven neuroblastoma 
pathogenesis are reported.  
First SULF2 was identified as playing a unique pro-tumorigenic role 
among the numerous enzymes controlling the sulfation of HSPG in NBL. Both 
SULF1 and SULF2 have been shown to be involved in the pathogenesis of a 
variety of cancers. They are highly expressed in hepatocellular carcinoma, 
head and neck and pancreatic cancer, in lung adenocarcinoma and squamous 
cell carcinoma, where their expression is typically associated with more 
aggressive behaviour and poorer clinical outcomes [Rosen and Lemjabbar-
Alaoui, 2010]. In Chapter 3 we showed for the first time that SULF2 is 
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specifically overexpressed in a subgroup of NBL cells in which MYCN plays an 
important role. SULF2 expression in vivo in primary human NBL tumours has 
subsequently been investigated (see Chapter 5).  
Data from this chapter suggest that SULF2 mediates the oncogenic effect of 
MYCN by increasing cell proliferation and survival through a yet to be 
determined mechanism that involves increased cell cycle entry and decreased 
spontaneous apoptosis.  
In the previous chapter our immunofluorescence studies demonstrated lower 
levels of sulfation in HSPG in cells expressing SULF2. This raises the 
possibility that SULF2 may promote the release of growth factors and other 
ligands from undersulfated HSPG, allowing them to interact with their respective 
receptors at the cell surface.  In support of this concept is the recent 
observation that in malignant glioma, loss of SULF2 expression decreases 
PDGF-PDGFRα interaction and PDGFR-mediated activation of the mitogen 
activated protein kinase (MAPK) pathway [Phillips et al., 2012]. This resulted in 
a growth inhibition in-vivo, in particular in a subset of gliomas that are more 
dependent on exogenous growth factors [Phillips et al., 2012]. Neuroblastoma 
cells express a variety of receptor tyrosine kinases (RTK) such as neurotrophin 
tyrosine kinase receptor (NTKR), insulin-like growth factor receptor (IGFR), C-
kit, VEGFR, epithelial growth factor receptor (EGFR) and PDGFR [Nilsson et 
al., 2010; Fakhari et al., 2002]. It is conceivable that as shown in glioma and 
breast cancer cells [Brodeur, 2003], SULF2 promotes the release of these 
heparin (HS)-bound growth factors and allows them to better interact with the 
receptors. One possible candidate for the activity of SULF2 is NTKR2 (TRKB), 
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which is abundantly expressed in MYCN-A tumours [Poluha et al., 1995]. Brain-
derived neurotrophic factor (BDNF) is the ligand for TRKB, which via a 
paracrine and autocrine loop, promotes tumour growth, drug resistance and 
angiogenesis in neuroblastoma [Brodeur, 2003; Light et al., 2012]. Like many 
other neurotrophic and growth factors, BDNF binds to oversulfated 
proteoglycans [Nandini et al., 2004]. There is presently no data supporting the 
concept that SULF2 could regulate BDNF-TRKB interaction. However the 
published observation that SULF1 and SULF2 positively regulate glial cell-
derived factor (GDNF)-mediated signalling and oesophageal innervation [Lui et 
al., 2012], suggests that SULF2 could regulate neurotrophic factor-mediated 
signalling. This line of investigation is currently the focus of further work. 
Second, another important observation reported in this chapter is that 
SULF2 is a possible downstream target of MYCN and that its protumorigenic 
function is independent of MYCN. This was first suggested in the previous 
chapter by the striking observation that SULF2 was specifically overexpressed 
in neuroblastoma cell lines with MYCN amplification and high levels of MYCN 
protein expression. A causal relationship between MYCN expression and 
SULF2 expression was then established by demonstrating that SULF2 was a 
downstream target of MYCN since its expression was found to be dependent 
on MYCN expression. The data establish that SULF2 not only contributes to 
MYCN oncogenesis but is a downstream target of MYCN expression. Over the 
last few years, a large number of transcriptional targets of MYCN have been 
reported through the use of expression array analysis, chromatin 
immunoprecipitation and serial analysis of gene expression (SAGE). Initial 
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studies using SAGE identified mainly genes involved in ribosome biogenesis 
and protein synthesis [Boon et al., 2001] but more recent studies included a 
larger variety of genes including miRNA [Buechner and Einvik, 2012]. SULF2 
has been reported to be a direct downstream transcriptional target of p53 and 
to mediate some aspect of p53 function such as DNA damage induced 
senescence [Chau et al., 2009]. Interestingly, SULF2 was recently identified 
among 36 genes down-regulated in 2 MYCN-A neuroblastoma cell lines treated 
with the bromodomain and extra-terminal domain (BET) inhibitor JQ1, that 
downregulates MYCN and its transcriptional program [Puissant et al., 2013]. By 
demonstrating that SULF2 overexpression increases the viability of NB cells 
independently of MYCN expression, evidence is provided that the pro-
tumorigenic function of SULF2, although regulated by MYCN, is MYCN-
independent. 
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Chapter 5: In-vivo expression and alterations of SULF2 in neuroblastoma  
 
5.1. Introduction  
 
In Chapter 4 we showed that amongst several enzymes that generate and edit 
the HS chain, SULF2 has a tumour promoting role in neuroblastoma. Studies 
showed that SULF2 is overexpressed in several human cancers where it plays 
a tumourigenic role [Bret et al., 2011]. Furthermore, studies have reported that, 
in vivo down-regulation of SULF2 resulted in a decreased tumour growth 
[Phillips et al., 2012; Lemjabbar-Alaoui et al., 2010]. 
We reported in previous chapters that, when compared to other cell lines, 
SULF2 is overexpressed in NBL cells that have MYCN amplification and that it 
promotes cell proliferation and decreases apoptosis in vitro. We also noticed 
that 6O-sulfation is decreased on the cell surface when SULF2 is 
overexpressed, which may lead to an increased release of growth factors and 
ligands into the extracellular space promoting the interaction with their 
receptors. In this Chapter we characterise the in vivo, expression status of 
SULF in human neuroblastoma tumours using large scale gene expression 
analysis and immunohistochemistry. To further confirm the observations made 
so far in this work, we also analysed the gene expression of SULF2 in two large 
and independent cohorts of NBL primary tumours. As SULF2 may have either 
promoting [Nawroth et al., 2007; Yang et al., 2005; Lai et al., 1998; Lai et al., 
2004; Lemjabbar-Alaoui et al., 2010] or inhibiting functions, depending on the 
signalling pathway [Dai et al., 2005; Peterson et al., 2010], we wanted to test 
the effects of alterating the levels of SULF2 in a neuroblastoma xenograft 
model by genetic modification of its expression.   
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Here we have examined 1) the expression of SULF2 in primary human NBL 
tumour samples, 2) the effects that modulation of sulfation (by altering SULF2 
expression) has on tumour cells survival in vivo.  
 
5.2. Hypothesis and Aims 
 
In this chapter we hypothesised that SULF2 is highly expressed in human 
primary NBL and that its alterations regulate tumour growth.  
To test this hypothesis the aims of this chapter were 
• To evaluate the expression of SULF2 in a cohort of primary human NBL 
tumour samples. 
• To further analyse the effects of SULF2 levels on human neuroblastoma 
growth in a xenograft model.  
 
5.3. Results 
 
5.3.1  SULF2 expression in primary human neuroblastoma tumours 
 
In order to validate the observations made in vitro on established cell lines, the 
expression of SULF2 in vivo in human NBL tissue was examined by 
immunohistochemistry (IHC). We wanted also to know whether the expression 
of SULF2 was restricted to NBL cells in situ and whether it was also present in 
the ECM and the surrounding cancer stroma cells. For this, a total of 65 primary 
human NBL samples were analysed; 22 tumours with MYCN amplification and 
unfavourable histology (UH), 23 tumours with UH but without MYCN 
amplification, and 20 tumours with favourable histology (FH) and without MYCN 
amplification. The staining of SULF2 was predominantly present in the plasma 
membrane and in the pericellular space surrounding tumour cells, although 
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some cells showed a marked cytoplasmic staining (Figure 5.1).  
 
 
Figure 5.1 Analysis of SULF2 expression in FFPE sections of primary human 
neuroblastoma tumours. Representative sections of tumours stained with an anti 
SULF2 antibody. (i and ii) MYCN-A and unfavourable histology (UH), (iii and vi) MYCN-
NA and unfavourable histology (UH) and (v and vi) are MYCN -NA with FH. Scale bar 
= 20 μm. 
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Stage 4S NBL (without MYCN A) showed weak immunoreactivity for SULF2 
(Figure 5.2). Therefore, the expression of SULF2 was apparently restricted to 
NBL cells.  
 
Figure 5.2 SULF2 expression in stage 4S NBL tumour. (A) Overall a weak SULF2 
staining across the tissue section. (B) Higher magnification of Homer-Wright rosettes 
with a halo of differentiated neuroblasts showing a weak to moderate immunoreactivity 
for SULF2 and non-stained neuropil at the centre. Scale bars are 20 μm. 
 
We noticed that there was a clear consistency amongst tissue sections when 
stained with the anti-SULF2 antibody. This was very prominent when 
comparing tissue sections that belonged to the MYCN amplified group versus 
the MYCN non-amplified ones (favourable histology); indicating that perhaps 
MYCN amplification was the crucial factor. However, sections belonging to the 
MYCN non-amplified and unfavourable histology showed some potentially 
different expression levels of SULF2. Owing to the expression patterns of 
SULF2 in NBL tissue a manual quantification of the immunoreactivity was 
difficult. We decided to measure the optical density (OD) of the 
immunoreactivity by colour deconvolution as the best option for our experiment. 
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This is a fast and quantitative method that can be used on standard RGB 
(red/green/blue) images acquired with a standard digital camera. Other 
methods such the “area method” using the ‘ImageJ’ thresholding tool were 
found to be time consuming and less reproducible. The IHC data were then 
quantified by colour deconvolution and optical density (OD) reading of digital 
images obtained from stained FFPE tissue sections as described in Materials 
and Methods. The method allowed a good separation of the DAB staining 
obtained with the anti-SULF2 antibody from the haematoxylin component 
(Figure 5.3). 
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Figure 5.3 Representation of colour deconvolution of SULF2 
immunohistochemistry in a MYCN amplified NBL tissue section. (A) NBL tissue 
section with a strong immunoreactivity for SULF2 with DAB (brown) and hematoxylin to 
stain nuclei (blue). Colour deconvolution results separating the contributions of 
hematoxylin (B) and DAB (C) to the original image. Scale bars are 20 μm. 
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The OD analysis (Figure 5.4) indicated a strong level of SULF2 expression in all 
MYCN-A tumours and an almost complete absence of expression in MYCN-NA 
tumours, whether they were of favourable or unfavourable histology (p= 
0.0001); this clearly indicated that SULF2 expression was linked to MYCN 
expression and not to other markers of unfavourable outcome independent of 
MYCN. The results for the NBL tumours analysed are shown in Table 5.1. 
 
 
Figure 5.4 Colour deconvolution analysis of SULF2 staining in human NBL 
tissue samples. Quantification of the immunohistochemistry data was obtained by 
colour deconvolution of DAB staining as described in Materials and Methods. The data 
represent the mean (+SD) OD obtained from 10 fields (20x) for each tumour section 
from MYCN-A (n=22), MYCN-NA, UH (n=23) and MYCN-NA, FH (n=20) tumours as 
shown in Table 5.1. ****p<0.0001. 
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Table 5.1 Neuroblastoma tissue samples data and OD measurements. A total of 65 
primary human NBL tumours were analysed. Information includes age, primary tumour 
location, stage, histology subtype, MKI, MYCN status, DNA index and OD 
measurements by colour deconvolution. MKI=mitosis-karyorrhexis-index; (high, 
≥200/5,000 cells, intermediate, 100-200/5,000 cells and low, <100/5,000 cells). MYCN: 
A (amplified), NA (non-amplified); and Stage: 1 to 3: non-metastatic; 4: metastatic; 4S: 
metastatic with good prognosis. DNA index (1 or >1); Diff+ grade of neuroblastic 
differentiation: differentiated, poorly differentiated and undifferentiated. Histology: FH 
(Favourable Histology) and UH (Unfavourable Histology). 
No. Age at diagnosis Primary site Stage Subtype Histology MKI MYCN DNA index Average OD SD of OD
1 10mo adrenal gland 4 poorly differentiated UH High A 1.1 0.0027 0.001992496
2 2y0mo retroperitoneum 4 poorly differentiated UH High A 1.877 0.3091 0.248114242
3 2y8mo adrenal gland 4 poorly differentiated UH High A 1 0.1939 0.042128442
4 1y7mo retroperitoneum 4 poorly differentiated UH High A 1.675 0.0295 0.018730881
5 3y3mo adrenal gland 4 poorly differentiated UH Intermediate A 1 0.0972 0.035885966
6 2y8mo mediastinum 4 poorly differentiated UH High A 1.422 0.1223 0.025680735
7 1y3mo adrenal gland 4 poorly differentiated UH High A 1.624 0.0582 0.042359791
8 6y1mo adrenal gland 4 poorly differentiated UH High A 1 0.0834 0.022527494
9 1y10mo retroperitoneum 4 poorly differentiated UH High A 1 0.0188 0.015517873
10 1y11mo abdomen 4 poorly differentiated UH High A 1.875 0.0197 0.016469964
11 1y3mo retroperitoneum 4 poorly differentiated UH High A 1 0.0365 0.013236271
12 1y7mo abdomen 4 poorly differentiated UH High A 1 0.0574 0.034012183
13 1y9mo abdomen 4 undiff UH High A 1 0.2783 0.05787682
14 2y0mo abdomen 4 poorly differentiated UH High A 1.727 0.1403 0.047433617
15 1y0mo adrenal gland 4 poorly differentiated UH Intermediate A 1 0.2284 0.061628232
16 1y11mo adrenal gland 4 poorly differentiated UH Intermediate A US 0.0494 0.032324485
17 2y8mo adrenal gland 4 poorly differentiated UH High A 1 0.4873 0.080288318
18 11mo abdomen 4 poorly differentiated UH High A 1 0.5881 0.062665786
19 5mo adrenal gland 2B poorly differentiated UH High A 1.704 0.2159 0.04150953
20 4y2mo abdomen 4 undiff UH High A US 0.4260 0.099869974
21 4y9mo abdomen 4 poorly differentiated UH High A 1.594 0.0538 0.008393583
22 3y7mo abdomen 4 poorly differentiated UH High A 1.66 0.0223 0.004559016
1 6y2mo adrenal gland 4 poorly differentiated UH Intermediate NA 1 0.0018 0.002083645
2 4y1mo posterior mediastinum 3 poorly differentiated UH Intermediate NA 1 0.0057 0.003749105
3 8y3mo retroperitoneum 2A poorly differentiated UH Low NA 1.42 0.0001 9.50145E-05
4 1y6mo adrenal gland 1 poorly differentiated UH Intermediate NA 1.628 0.0002 0.000195319
5 1y10mo neck 4 poorly differentiated UH Intermediate NA 1.332 0.0019 0.001140052
6 2y3mo pelvis 4 poorly differentiated UH Intermediate NA 2.373 0.0093 0.007758074
7 3y10mo retroperitoneum 4 poorly differentiated UH Intermediate NA 1 0.0030 0.002563447
8 2y7mo adrenal gland 4 poorly differentiated UH Low NA 1.718 0.0025 0.004247806
9 1y11mo adrenal gland 4 poorly differentiated UH Intermediate NA 1 0.0180 0.01387578
10 4y5mo posterior mediastinum 4 poorly differentiated UH High NA 1.067 0.0091 0.002960215
11 9y5mo retroperitoneum 4 poorly differentiated UH Intermediate NA 1.466 0.0088 0.004694647
12 6mo adrenal gland 4 poorly differentiated UH High NA 1.953 0.0036 0.003134973
13 3y9mo adrenal gland 4 poorly differentiated UH Intermediate NA 1 0.0087 0.006636563
14 5y7mo adrenal gland 4 poorly differentiated UH Low NA 1 0.0062 0.005790541
15 4y6mo suprarenal mass 4 poorly differentiated UH Intermediate NA 1 0.0011 0.000750488
16 3y11mo retroperitoneum 4 poorly differentiated UH Intermediate NA 1.852 0.0007 0.000660758
17 3y9mo no data 4 poorly differentiated UH Intermediate NA 1 0.0012 0.001254473
18 3y7mo retroperitoneum 4 poorly differentiated UH Intermediate NA 1.992 0.0025 0.001914191
19 4y10mo abdomen 3 poorly differentiated UH High NA 1.613 0.0000 7.16375E-06
20 3y5mo abdomen 4 poorly differentiated UH Low NA 1 0.0014 0.000922693
21 9y6mo paraspinal mass 4 poorly differentiated UH Low NA 1.411 0.0000 1.89826E-05
22 3y8mo neck 4 poorly differentiated UH high NA 1 0.0005 0.000329807
23 8y5mo retroperitoneum 2B poorly differentiated UH Intermediate NA 1 0.0000 7.66176E-06
1 9mo adrenal gland 1 poorly differentiated FH Intermediate NA 1.614 0.0000 1.58005E-05
2 1mo abdomen 1 poorly differentiated FH Low NA 1.525 0.0000 5.68577E-05
3 3mo retroperitoneum 3 poorly differentiated FH Intermediate NA US 0.0001 4.5818E-05
4 6mo adrenal gland 4 poorly differentiated FH Intermediate NA 1.437 0.0001 6.35906E-05
5 25days retroperitoneum 2B poorly differentiated FH Intermediate NA 1.399 0.0001 5.27509E-05
6 2mo adrenal gland 2B poorly differentiated FH Low NA 1.183 0.0002 0.0001847
7 3mo paravertebral 2A poorly differentiated FH Low NA ND 0.0002 0.000226281
8 1mo adrenal gland 1 poorly differentiated FH Low NA 1.471 0.0002 0.000241229
9 6mo retroperitoneum 4s poorly differentiated FH Low NA 1.524 0.0003 0.000390292
10 5mo posterior mediastinum 1 poorly differentiated FH Low NA 1.486 0.0003 0.000227276
11 1y10mo retroperitoneum 3 differentiating FH Low NA 1.415 0.0003 0.000396476
12 2mo adrenal gland 4s poorly differentiated FH Intermediate NA 1.47 0.0004 0.000360389
13 1y0mo retroperitoneum 3 poorly differentiated FH Low NA 1.48 0.0005 0.000433776
14 2mo retroperitoneum 2B poorly differentiated FH Low NA 1.357 0.0007 0.000508782
15 1mo adrenal gland 4S poorly differentiated FH Low NA 1.18 0.0008 0.000366443
16 8y8mo abdomen 4 poorly differentiated FH Intermediate NA 1 0.0008 0.000920497
17 1y4mo retroperitoneum 4 poorly differentiated FH Intermediate NA 1.252 0.0012 0.001652937
18 11mo neck 3 poorly differentiated FH Intermediate NA 1.17 0.0020 0.001199686
19 5mo retroperitoneum 3 poorly differentiated FH Low NA 1.298 0.0022 0.003131543
20 1w adrenal gland 4s poorly differentiated FH Low NA 1.24 0.0002 0.0018045
 90 
5.3.2 Microarray analysis of human neuroblastoma tumours 
 
To further confirm the link between SULF2 and MYCN expression in primary 
neuroblastoma tumours, information was obtained through an analysis of gene 
expression arrays in a cohort of 416 tumour samples from the patients enrolled 
in GPOH clinical trials [Asgharzadeh et al., 2012]. This analysis revealed a 
statistically significant higher level of expression of SULF2 mRNA in tumours 
derived from patients with high-risk disease and MYCN amplification compared 
to tumours of patients with high risk disease, but lacking MYCN amplification, 
and tumours of patients with low risk disease (p < 0.0001; Figure 5.5). Similar 
results were obtained from a second cohort of 162 samples obtained from 
children enrolled in the COG clinical trials (p < 0.0005). These data provided 
further support to the observation that SULF2 is a direct target of MYCN in 
neuroblastoma and contributes to its tumourigenic function. 
 
Figure 5.5 Expression of SULF2 RNA by gene array expression analysis 
generated from primary tumours. Two cohorts of patients treated in clinical trials 
conducted by GPOH (n=416) and COG (n=162) were analysed. The data were 
analysed by comparing 3 groups according to their clinical risk stratification (HR-A = 
high risk with MYCN-A, HR-N = high risk with MYCN NA and LR = low risk). **** p< 
0.0001 in GPOH group and *** p < 0.0005 in COG group based on ANOVA. 
5.3.3 SULF2 in a xenograft model of neuroblastoma 
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To validate our hypothesis that SULF2 modulates tumour growth, we used a 
genetic approach to either overexpress or knock down the expression of SULF2 
in a xenograft model of NBL. To examine the consequences of SULF2 
expression on tumour growth, we developed gene expression constructs with 
either the active (SULF2) or inactive SULF2 (S2ΔCC), as described in the 
Methods chapter (section 2.6.2). These constructs were transfected into CHLA-
255 NBL cells, and injected into NOD/SCID mice (Figure 5.6). The harvested 
tumours showed an increase in weight for the SULF2 and also unexpectedly for 
the control group. Transduction with the mutated and inactive SULF2 (S2ΔCC) 
did not show any growth (Figure 5.6).  
 
 
Figure 5.6 Tumour size and body weight in NOD/SCID mice after SULF2 
overexpression. Size of the tumours (left) was evaluated until day 25 post injection. 
Both groups of CHLA-255 cells transfected with the control (scramble sequence) and 
or SULF2 overexpressing vector grew large tumours. As expected, cells with the 
mutated inactive SULF2 did not form tumours [Lemjabbar-Alaoui et al., 2010]. Graph 
on the right shows the body size in the three groups with equal values.  
 
To further examine the effects of SULF2 on NBL cells in vivo, we used a 
xenograft model in NOD/SCID mice. We selected the human neuroblastoma 
cell SK-N-BE(2), a cell line that is known to have high levels of SULF2 and 
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MYCN expression, and transfected with a tet-inducible shRNA-targeting SULF2 
vector (developed specifically in these studies and described in Methods, 
section 2.6.3). The cells were tested for doxycycline toxicity and grown in 
culture at a doxycycline concentration of 1 μg/ml to activate the shRNA to 
knockdown the expression of SULF2 (Figure 5.7). Transfected cells were 
positive for GFP and sorted by FACS to obtain a high concentration of 
transfected cells prior the injection into NOD/SCID mice (Figure 5.8).  
 
 
 
Figure 5.7 Western blot of SK-N-BE(2) cells transfected with the tet-inducible 
shRNA-targeting SULF2 vector  and  treated with doxycycline. The H1 promoter 
was activated by the presence of doxycycline and induced a knock down of SULF2. 
Scr, scramble (control) sequence maintained the elevated levels for SULF2. 
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Figure 5.8 FACS sorting for GFP positive cells. Cells transfected with tet-inducible 
shRNA-targeting SULF2 vector are positive for GFP and have high transfection 
efficiency by microscopy (images on left, for x, y and z = 3 panel types) and by FACS 
sorting (image far right). Bar scale is 20 μm. 
 
 These transfected SK-N-BE(2) cells were then injected subcutaneously at 2 
sites in NOD/SCID mice and monitored for growth (Figure 5.9 A and B). In each 
group (n=9 or 10 mice), 5 mice received doxycycline in the drinking water (to 
activate the knockdown of SULF2). In the 9 mice injected with SKNBE(2) 
pKRAB-SCR vector(scramble sequence), 8 mice developed bilateral tumours 
and the administration of doxycycline had no effect on the rate of tumour growth 
(one mouse in the doxycycline negative group did not develop tumours). By day 
31 after tumour cell implantation, all mice had to be euthanized because one or 
both tumours had reached a volume greater than 1,500 mm3 (Figure 5.9 A). 
In the group of mice injected with SKNBE(2) pKRAB-SULF2 vector, treatment 
with doxycycline resulted in a tumour formation rate  of 50 % only and in a 
significant delay in tumour growth with an average time for tumours to reach 
500 mm3 of 28 ±3.7 days compared to a tumour formation rate of 75 % and 100 
% and an average time for tumours to reach 500 mm3 of 20±5 and 18±2.3 days 
in the pKRAB-SCR control group (untreated and treated with doxycycline 
respectively). Unexpectedly, the pKRAB-SULF2 group untreated with 
doxycycline, although having an expected tumour formation rate of 100 % 
showed a delay in tumour growth with an average time to reach 500 mm3 25 ± 
3.2 days. This suggested that SULF2 expression might have been down 
regulated in this group due to the leakiness of the vector. This was confirmed 
by an analysis of SULF2 mRNA expression in tumour samples by RT-PCR 
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(Figure 5.9 C), which revealed a statistically significant decrease in SULF2 
expression in the pKRAB-SULF2 subgroup (average ΔCT of 12.7 ± 0.8) not 
treated with doxycycline (p=0.008). An analysis of the expression of SULF2 
protein by immunohistochemistry (Figure 5.9 D) confirmed the down regulation 
of SULF2 in tumours derived from mice implanted with pKRAB-SULF2 cells and 
untreated with doxycycline. The data in this group of mice are explained by the 
leakiness of the pKRAN-SULF2 vector and further demonstrate that down 
regulation of SULF2 expression in MYCN A cells inhibits tumourgenesis.  
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Figure 5.9 Loss of SULF2 expression in MYCN tumour cells inhibits tumour 
formation and growth. MYCN-A-SKNBE(2) cells were stably transfected with 
pKRABDULF2 and pKRABSCR and sorted for GFP expression. (A), Cells were 
injected in the right and left flank of NOD/SCID mice and monitored for development 
and growth. The graph represents the tumour diameter (in mm3) of each tumour 
measured at the indicated times in the four groups. (B), The graph represents the 
percentage of tumours that developed in the 4 groups of mice. (C), pRT-PCR analysis 
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for SULF2 mRNA expression in tumours harvested at time of sacrifice. (D), Analysis of 
SULF2 expression by immunohistochemistry in sections of tumours derived from the 4 
groups of mice. Scale bar = 20 μm. 
 
In conclusion, in this Chapter we have demonstrated that SULF2 is significantly 
increased at protein and mRNA levels in a large cohort of human primary 
neuroblastoma when MYCN is amplified. We also demonstrated in an in vivo 
model that knock down of SULF2 in MYCN A NBL cells inhibits tumour growth.  
This data are encouraging and are consistent with SULF2 having a pro-
tumourigenic role in neuroblastoma. 
 
 
5.4. Discussion 
 
In the previous chapters we observed that SULF2 was strikingly overexpressed 
in NBL cell lines that are MYCN amplified. In this Chapter we provide the first 
evidence that SULF2 is also over-expressed in a subgroup of primary human 
NBL tumours with the amplification of MYCN, a marker for poor survival, 
consistent with an important role for this endosulfatase in cancer. SULF2 was 
almost absent in the tumour tissue of MYCN non-amplified tumours and with 
favourable histology. The observation that SULF2 is increased in NBL patients 
with poor prognosis is similar to the previously reported findings in human 
oesophageal cancer and glioma [Lui et al., 2012; Phillips et al., 2012]. Often 
there has been discrepancy between in vitro and in vivo findings regarding 
SULFs. Both enzymes showed signalling inhibition for certain growth factors in 
vitro but, had antagonistic activities for cell proliferation and angiogenesis in in 
vivo [Lai et al., 2004; Lai et al., 2008; Uchimura et al., 2006; Morimoto-Tomita et 
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al., 2005]. This could be due to distinct effects on spatially separate substrates. 
For example, 6O-desulfation of cell surface HS could result in the reduction of 
growth factor binding at the cell, whereas 6O-desulfation of HS in the matrix 
could cause a release of growth factors from the ECM. 
The ex vivo studies in human NBL tissue were extended by showing that 
SULF2 mRNA levels are significantly elevated in a large number of non-
correlated primary human NBL tumours. We have demonstrated in two large 
cohorts (416 patients in the CPOH cohort and 162 from the COG cohort 
described, Figure 5.4) that SULF2 expression in primary NBL tumours was 
significantly elevated in high-risk NBL when MYCN was amplified compared to 
high-risk without MYCN amplification and low-risk. It is notable that there is no 
huge difference in the overall survival of children with HR disease. Those 
dependent on MYCN have been shown to have shorter time to progression and 
in general shorter time to death compared to patients whose tumour does not 
have MYCN amplification [London et al., 2011]. However, patients in the HR 
group without MYCN eventually succumb to their disease, and hence have 
similar overall outcomes.  NBL patients with HR and MYCN A have a slightly 
but not significantly poorer outcome than HR patients with MYCN NA [London 
et at, 2011]. MYCN amplified NBL tumours are thought to use different 
mechanism to evade the immune system and have different metabolic profiles 
[Song et al., 2009]. It has been noted that MYCN NA HR patients tend to utilise 
the tumour microenvironment and express different pathways with higher 
proliferation capabilities [Metelitsa et al., 2004], and this would also be 
consistent with the observed effects of SULF2 on proliferation, and other effects 
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that might be rendered by SULF2 induced alterations in HS sulfation. Thus, 
SULF2 levels are quite conceivably a key aspect that explains at least in 
significant part the differences between the NBL sub-types.  
Interestingly, both SULF2 and MYCN gene transcripts were found to be 
strongly over-expressed in B cells of patients with chronic lymphocytic 
leukaemia (CLL) resistant to treatment with fludarabine [Moussay et al., 2010]. 
This was seen in both in vivo and in vitro with both genes over-expressed in 
samples of resistant patients obtained before treatment. Based on our previous 
in vitro findings and on the central role that SULF2 has in promoting 
tumourigenesis, we hypothesised that its forced expression in a MYCN non-
amplified NBL cell line will induce tumour growth in vivo. Unfortunately, our 
initial xenograft experiments with forced SULF2 expression described in this 
chapter did not reveal the expected results in full; although the NBL cells with 
SULF2 overexpression showed good tumour growth similar to the control 
(scrambled construct). In contrast, the NBL cells overexpressing catalytically 
inactive SULF2 (S2DCC) did not grow; this was also an unexpected finding, as 
an inactive SULF2 should not have arrested tumour formation to this extent. 
The function of the mutated SULF2 is not clear; it is however know to 
accumulate in the lipid raft with a more even distribution on the cell surface 
[Tang and Rosen, 2009]. Here the mutated SULF2 could compete with the 
endogenous SULF2 to bind to target sequences and block them. As known 
from the literature [Lemjabbar-Alaoui et al., 2010] and our data from Chapter 4, 
an overexpression of SULF2 should have promoted tumour growth compared to 
the control. Cells with forced overexpression of SULF2 are known to have a 
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transformed phenotype with increased proliferation and survival, whereas 
transfection with the mutated and inactive SULF2 did not show any changes 
[Lemjabbar-Alaoui et al., 2010]. Thus we could not confirm entirely in vivo our 
hypothesis that SULF2 has a tumour promoting role in NBL. It is not clear why 
the scrambled control and the inactive SULF2 gave unexpected results, and 
further experiments are required. The possibilities for the incongruent results 
obtained could lie in a technical problem with the transduction of the 
sequences, as they can be lost over a number of cell cycles and cells from the 
inactive SULF2 might have lost their viability during the injection into the mice. 
To avoid the possibility that the cells will lose expression of the shRNA 
construct, further repeats of this set of experiments after a clonal selection have 
being carried out. However, this experiment was not repeated due to a lack of 
time available in the fellowship. In contrast, the SULF2 knockdown in vivo 
experiment has provided some good results, consistent with our hypothesis, 
that the effect of genetic ablation of SULF2 on neuroblastoma growth will match 
the reports in the literature that reported a pro-tumourigenic effect of SULF2 
[Nawroth et al., 2007, Yang et al., 2005, Lai et al., 2005, Lemjabbar-Alaoui et al., 
2010].  
In conclusion, our data have demonstrated that SULF2 is elevated in high-risk 
neuroblastoma patients with MYCN amplification, a marker of poor outcome 
and therapy resistance; and its promotes tumourgenesis in an in vivo model. 
SULF2 might represent a target for therapeutic intervention in NBL as reported 
for other cancers with elevated SULF2 levels and clearly warrants further 
investigation. 
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 Chapter 6. Conclusions and Future Directions 
6.1 Summary of key findings 
This thesis sets out the findings of investigations into the role of HS, and in 
particular its sulfation patterns, in neuroblastoma. All the data presented in this 
thesis come from in vitro studies using established cell lines, human primary 
neuroblastoma tumours, and preliminary experiments with in vivo models using 
xenografts in immunodeficient mice.  
 
The major findings presented in this thesis are: 
• Amongst several HS biosynthetic and modification enzymes SULF2 is 
over-expressed in neuroblastoma cell lines when MYCN is amplified.  
• SULF2 is also over-expressed in a large cohort of human primary high-
risk neuroblastoma samples that have MYCN amplification 
• SULF2 regulates neuroblastoma cell survival independently of MYCN 
status  
• SULF2 is a direct target of MYCN in neuroblastoma and contributes to its 
tumourigenic functions. 
The above findings strongly support the main initial hypothesis of this 
study, that HSPGs and their sulfation status are involved in the 
regulation of NBL cell survival. 
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6.2 General discussion  
The studies presented in this thesis have focussed on the role of SULF2 in 
neuroblastoma and the effects of its manipulation on tumour growth. It makes a 
contribution towards understanding the role of glycosylation in cancer and in 
particular reports the novel implications of a key enzyme responsible for the HS 
sulfation status in neuroblastoma.  
Neuroblastoma is still a lethal disease for many patients despite multimodal 
treatment strategies that have reached their maximum potential, and new 
treatment approaches are required. MYCN amplification still plays a central role 
in the pathology of this cancer. MYCN is the major negative prognostic marker 
in NBL with amplification in 25 % of primary tumours and nearly half of high-risk 
cases [Maris and Matthay, 2010; Brodeur 1984]. It is known to play a crucial 
role in proliferation, differentiation and apoptosis. MYCN expression is essential 
during normal neural crest development and other neuronal organs and 
becomes down-regulated only towards the end of terminal tissue differentiation 
[Thomas et al., 2004]. Importantly, MYCN alone is sufficient for transformation 
[Weiss et al., 1997]. Despite many genomic studies, it has not been possible to 
identify new molecular targets in NBL [Molenaar et al., 2012] and the need to 
study the role of the microenvironment of cancer cells is becoming more widely 
accepted [Hanahan and Coussen, 2012]. 
The hypothesis of the work presented here was based on some preliminary 
data that indicated altered HS signatures amongst NBL cells and primary 
tumours with an increase in 6O-sulfation in HS chains (see Appendix 1). Here, 
a panel of 16 cancerous cell lines, of which 8 were NBL with various NMYC 
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amplification status, was screened for the major HS biosynthetic and 
modification enzymes. It was established that SULF2 was significantly 
increased in all MYCN amplified NBL cell lines tested. Increased levels of 
SULF2 expression would be expected to lead to decreased levels of 6-O 
sulfation as shown in our preliminary data (see Appendix 1) and in the literature 
[Phillips et al., 2012; Lemjabbar-Alaoui et al., 2010]; however further 
biochemical work is needed to study the sulfation status in NBL cell lines.  
This data was confirmed in a large cohort of human primary NBL samples with 
MYCN amplification at both mRNA and protein levels. Manipulation of SULF2 
expression by siRNA was found to induce cell apoptosis and reduce cell 
proliferation, without affecting the expression of MYCN. Forced over-expression 
of SULF2 in the absence of MYCN increased cell proliferation, consistent with 
previous studies [Lemjabbar-Alaoui et al., 2010] and from observation made in 
other human cancer types such as chronic lymphatic leukaemia [Moussay et 
al., 2010]. Our work suggests that SULF2 is a down stream target of MYCN and 
furthermore that it mediates the oncogenic effect of MYCN by a mechanism not 
yet identified. The data presented in this thesis clearly indicate that a direct 
result of SULF2 overexpression is enhanced proliferation and reduced 
apoptosis, both of which would be consistent with more aggressive tumour 
behaviour. There may well be other mechanisms related to tumour 
dissemination, which could result from over-expression of SULF2 and its 
consequences in terms of altered HS sulfation patterns and thus interactions 
with the extracellular matrix.  Further work is needed on in vivo model studies of 
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forced over-expression of SULF2 in NBL to investigate these mechanisms in 
more detail.   
Several transcription targets for MYCN have been identified by a ChiP assay 
study, one of which is the tumour suppressor p53, which also has SULF2 as a 
transcriptional target [Chau et al., 2009]. Induced expression of MYCN resulted 
in increased SULF2 expression, but not vice versa, strongly indicating that 
SULF2 is a down stream target of MYCN. It has always been considered that 
MYCN is a non-druggable target. Several therapeutic strategies investigated 
included small molecule inhibition to disrupt the Aurora-A/MYCN complex  
[Brockmann et al., 2013] and the PI3K/AKT/mTOR network [Gustafson and 
Weiss, 2010]. Despite being promising potential therapeutic approaches, these 
also target other kinases and biological processes and organs systems raising 
concerns about off-target effects and toxicity. However, recent studies found 
that inhibition of the BET bromodomain by JQ1 knocked down the expression of 
MYCN, impaired growth and induced apoptosis [Puissant et al., 2013]. In this 
study several genes responded to the treatment by being knocked down, and 
SULF2 was part of the response signature. Interestingly many of the genes 
(such as PHOX2B and SULF2) are associated with neuronal crest 
differentiation.  
Recently SULF2 has been considered important to drive tumourigenesis 
through the action of several growth factors [Phillips et al., 2012; Bret et al., 
2011; Lemjabbar-Alaoui et al., 2010]. Several treatment strategies in the 
modulation of heparan sulfate and SULF2 have been the focus of recent 
studies. PI-88, initially developed as an anti-heparanase agent (which is also 
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anti-angiogenic and inhibits some growth factors), has also been shown to have 
SULF2 inhibitory functions [Hossain et al., 2010]. PI-88 has been tested in 
clinical trials for liver cancer but was found to have a lack of efficacy due to 
dosage limitations of toxicity and off-target effects [Wang et al., 2013].  In 
addition, other protease inhibitors suppress SULF2 expression levels in some 
cancer cell lines, and reduce tumour size in mice xenografts [Khurana et al., 
2013; Garteiser et al., 2010]. Some of these inhibitors have been tested in 
clinical trial for the treatment of lung and prostate cancer but unfortunately, 
showed some serious side effects due to their broad range of activities 
[Kudchadkar et al., 2008; Schelwies et al., 2010]. Other therapeutic possibilities 
would include the development of small molecule inhibitors or antibody-based 
therapies targeted more specifically against SULF2. However, the success of 
further treatments is dependent on a better knowledge of the mechanisms by 
which SULF2 plays roles in neuroblastoma behaviour, particularly when MYCN 
is amplified. Additionally, the information available so far SULF2 suggests to 
have an extremely complex molecule; this may improve the chances of it being 
a successful target for drug development.   
 
6.3 Concluding remarks and future investigations 
This thesis set out to investigate the relationship between sulfation of HS and 
neuroblastoma. All the data presented in this thesis derive from in vitro studies  
using establishes cell lines and primary human neuroblastoma tumours. 
Experiments in vivo used xenografts in immunedeficient NOD/SCID mice.  
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Our data point to SULF2 as regulator of HS sulfation, being downstream of 
MYCN and an important contributor to its oncogenic function. They also 
emphasize the critical role that HSPGs could play as regulators of survival and 
proliferation in neuroblastoma, a subject that has not been investigated so far. 
 
A number of avenues for future investigations arise from the work presented in 
this thesis: 
6.3.1 Effects of SULF2 overexpression in the mouse xenograft model 
The experiments from which preliminary data is described in Chapter 5 will be 
completed, in order to assess the effect of SULF2 overexpression down in vivo.  
6.3.2 To characterise biochemical changes in HS in neuroblastoma. 
Some preliminary studies on HS structure were undertaken and are presented 
in Appendix 3. We aim to further characterise, initially by disaccharide 
composition analysis, the sulphation status of HS in neuroblastoma cell lines 
and human tissue, and in particular the consequences of over-expresssion or 
siRNA knock-down of SULF2.  These experiments will allow a better 
understanding of the functional effects of SULF2, and the mechanisms by 
which changes in HS mediate biological effects in NBL.   
 
6.3.3 To study the signalling pathways regulated by SULF2 in 
neuroblastoma 
Using our established methods for genetically altering the expression of SULF2, 
we aim to examine the effects on regulation of critical growth factor signalling 
pathways in NBL.  This is expected to include FGFs and VEGF, but may reveal 
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additional growth factor targets of potential biological and therapeutic 
significance. Additionally because SULFs are expressed in soluble as well as 
cell-surface associated forms, SULF2 might also have non-cell autonomous or 
paracrine activity which needs to be addressed in future work. 
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Appendix 
Appendix 1 - Preliminary data that lead to the hypothesis of this thesis 
This Appendix shows some of the preliminary PhD work done as part of the 
Academic Clinical Fellowship in paediatric surgery by the author (VS). 
 
It was known that some heparan sulfate (HS) abnormalities were found in NBL 
in the 1980s [Hampson et al., 1983] and that elevated serum heparanase also 
correlates with poor prognosis in NBL [Shafat et al., 2007]. Initially when 
discovered, these HS abnormalities could not be pursued due to lack of 
technology that hampered its analysis. Also it became more apparent that NBL 
is a cancer of development where their few genetic mutations cannot explain 
entirely the complexity of their development and behaviour. The increasing 
evidence of the important role heparan sulfate as a regulator of cell interactions 
with the surrounding microenvironment became an important missing link. We 
started by hypothesising that HS is altered in NBL and that it regulates their 
phenotype.  
In our preliminary work that lead to the MRC Clinical Research Fellowship that 
sponsored this PhD study we used for the first time phage-display antibodies to 
HS to study HS expression in NBL cells. The phage display antibody HS3B7V 
(Appendix Figure 1.1) shows differential HS staining between the NBL cell line 
SH-5YSY (neuronal type) and SHEP (stromal type). SH-5YSY and SHEP are 
MYCN NA cell lines. We also analysed archival tumour sections and showed 
that HS is overexpressed in primary human NBL tumours relative to 
surrounding non-tumour tissue (Appendix Figure 1.2). Additionally we 
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demonstrated that NBL cell lines with different phenotypes vary 
characteristically in their HS expression with reciprocally altered sulfation in SH-
SY5Y compared to SHEP (Appendix Figure 1.3).  
 
Appendix Figure 1.1 Immunocytochemistry with a phage display antibody. 
HS3B7V (green immunofluorescence), differential HS staining between the NB cell line 
SH-5YSY (A, neuronal type) and SHEP (B, stromal type). Vimentin is stained in red. 
We demonstrated NBL cell lines with different phenotypes that vary characteristically in 
their HS expression with reciprocally altered sulfation in SH-SY5Y compared to SHEP 
(B). 
 
 
 
Appendix Figure 1.2 HS immunohistochemistry using 3G10 antibody. A 
representative stage 3 NBL tumour with a strong expression in the stroma and cell 
surface (A) and only a few HS positive cells in the normal adrenal gland.  
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Appendix Figure 1.3 High performance liquid chromatography (HPLC) 
disaccharide analysis. Graph bar showing the three principal sulfation (S) positions 
with differences in 2S and 6S between the NBL cell lines SHEP and SH-5Y-SY. 
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Appendix 2 - Chromatin immunoprecipitation (ChIP) assay 
The finding s from Chapter 3 and Chapter 4 suggested that SULF2 is a down 
stream target of MYCN. Here in this appendix we show a chromatin 
immunoprecipitation assay to test this hypothesis. 
 
The work of this appendix was done by Mueller Fabbri, MD, PhD and Kishore 
Challagundla, PhD at the Children’s Hospital Los Angeles (CHLA), USA. 
Appendix 2 - Material and Methods 
MYCN amplified SK-N-BE(2) cells were crosslinked with 1% formaldehyde for 
10 minutes at RT followed by quench the cross linking reaction with 1.25M 
glycine at RT for 5 minutes. Cells were washed 3 times with ice cold PBS and 
lysed with RIPA buffer [50 mM Tris (pH 8.0), 150 mM NaCl, 5 mM EDTA, 1 % 
NP-40, 0.1 % SDS, 0.5 % Sodium deoxycholate] and protease inhibitor cocktail 
on ice for 10 minutes. Cell lysates were sonicated for 15 seconds for 5 times 
using a sonicator (Q Sonica, Q125). The average chromatin fragment size after 
sonication was approximately 600-1000 bp. After centrifugation, the soluble 
chromatin fraction was recovered and pre-cleared for 30mins h at 4°C with a 
mixture of Protein A and G-conjugated beads (Santa Cruz Biotechnologies) 
then blocked with BSA and salmon sperm DNA. Chromatin was 
immunoprecipitated overnight at 4°C with either an IgG or anti-MYCN 
antibodies. After antibody incubation protein A/G beads were added to the 
immuno-precipitates for additional 2 hours at 4°C. Immunoprecipitates were 
washed twice with RIPA buffer, four times with IP wash buffer (100 mM Tris [pH 
8.5], 500 mM LiCl, 1 % NP-40, 1 % deoxycholic acid) and additional two more 
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times with RIPA buffer. Bound chromatin and input DNA were placed in elution 
buffer (50 mM NaHCO3, 1 % SDS) and reverse crosslinked. 
Immunoprecipitated DNA and input DNA were treated with RNase A and 
proteinase K and purified with a QIAquick PCR purification kit (Qiagen). 
Quantitative RT-PCR was performed with CFX96 Touch Real Time PCR using 
SYBR master mix (Biorad). All reactions were carried out in triplicate. 
Calculations were done using the ΔΔCt method. MYCN IP was normalized to 
IgG IP and presented as fold change of MYCN IPed DNA when compare to 
IgG. Primer sequences used in ChIP qRT-PCR analysis are F: 5’-
AGGCGATGGAAACTCGTTCT-3’ and R: 5’-CATGGCCTTGTTGACCCTTA-3’. 
Another portion of the cells were used for western blot analysis of MYCN. 
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Appendix Figure 2.1 SULF2 is a target gene of MYCN.  
(A) Diagram demonstrating the SULF2 gene location on Chromosome 20. Filled box 
indicate the exonic region amplified by ChIP-qPCR assay. Arrow indicates the 
transcription start point. (B) CHIP q-PCR assay showing the enrichment of MYCN on 
SULF2 gene promoter. ChIP-qPCR assays were conducted in SK-N-BE(2) cells using 
anti-MYCN antibody to detect the recruitment of endogenous MYCN at the SULF2 
gene promoter. (C) Western blot showing the expression of endogenous MYCN in 
ChIP assay and no product for the IgG..  
 
This assay showed that MYCN binds to the SULF2 promoter region. This 
supports our previous hypothesis in Chapter 4 that SULF is down stream of 
MYCN.  
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Appendix 3 - Disaccharide analysis 
 
In initial efforts to explore changes in HS sulfation at the biochemical level in 
response to altered SULF2 expression, we purified HS from different NBL cell 
lines and genetically altered counterparts, and examined their disaccharide 
composition by HPLC employing fluorescence detection. 
 
The work presented in this appendix is currently being performed by Becky 
Miller, PhD and Sophie Thompson, PhD at the University of Liverpool, UK. 
 
Appendix 3: Material and Methods 
HSPG extraction and purification of HSPGs using ion exchange 
chromatography : Cells were scraped from the flasks, sonicated and incubated 
at room temperature for 2 hours with agitation with TUT buffer (10 mM Tris 
base, 8 M urea, 1 % (v/v) Triton X-100, 1 mM Na2SO4, pH 8) at 1 mL/10 cm2. 
Extracted sample/conditioned medium was applied to 100 ml DEAE-Sephacel 
beads per 5 mL sample (pre washed and equilibrated in PBS) and incubated 
overnight at room temperature with gentle agitation. Void volume material was 
discarded and the DEAE beads were washed three times in 10 column volumes 
of PBS, followed by 10 column volumes of 0.25 M NaCl in PBS. Bound material 
containing HSPGs was eluted with 10 column volumes of 2 M NaCl in PBS. The 
eluant was desalted over two, in-line 5 ml HiTrap desalting columns using an 
AKTA FPLC system and freeze dried 
Digestion of HS into disaccharides: Freeze dried material was resuspended in 
heparin lyase buffer (100 mM sodium acetate, 0.1 mM calcium acetate, pH 7) 
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and 1.25 mU of heparinase I (heparitinase III) was added. Samples were 
incubated at 37°C. After 2 hours, 1.25 mU of heparinase III (heparitinase I) was 
added to samples and incubated for a further 2 hours at 37°C, followed by 1.25 
mU of heparinase II incubated for another 2 hours at 37°C. All three enzymes 
were then added to each sample at 1.25 mU and incubated overnight at 37°C. 
Digested samples were then made up to 0.5 M NaCl, incubated at 95°C for 5 
minutes and allowed to cool. 
C18 recovery of HS disaccharides: C18 spin columns (#89873, Pierce) were 
washed as per the manufacturer’s instructions. Each sample was added to a 
C18 column and centrifuged at 1,500 g for 1 minute. HS disaccharides present 
in the void volume were collected. Columns were washed three times with 
HPLC water and the washes added to the disaccharide samples. 
Sample clean up using graphite: Graphite spin columns were washed as per 
the manufacturer’s instructions. Samples were loaded onto the columns, mixed 
gently and incubated at room temperature for 10 minutes. Columns were then 
centrifuged at 3,000 g for 1 minute and the flow through discarded. The 
graphite was then washed three times with HPLC water and the bound 
disaccharides eluted in three washes of 40 % (v/v) acetonitrile, 0.5 % (v/v) TFA. 
Sampled were then dried to remove the acetonitrile and TFA. 
Fluorescent labelling of HS disaccharides: Freeze-dried HS disaccharides were 
labelled with BODIPY FL hydrazide (5 mg/ml; 4,4-difluoro-5, 7-dimethyl-4-bora-
3a, 4a-diaza-s-indacene-3-propionic acid hydrazide; Molecular Probes) as 
previously described [Skidmore et al., 2006; Skidmore et al., 2010]. Digested 
heparin control and HS disaccharide standards (Iduron, Manchester, UK) were 
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labelled in the same way. Labelled samples were applied to silica gel thin layer 
chromatography (TLC) aluminium plates and free BODIPY tag separated from 
labelled disaccharides with butanol. Labelled HS disaccharides were removed 
from the TLC plates and solubilised in HPLC grade water.  
Ethanol precipitation: Sample volume was reduced to ~ 200 ml and incubated 
on ice. Ice cold saturated ethanol was added to samples at a final concentration 
of 80 % (v/v) and incubated on ice for 15 minutes. Samples were then 
centrifuged at 13000 rpm and the supernatant containing the HS disaccharides 
removed and dried by speed vac. 
SAX-HPLC: SAX separations were performed on a Propac PA1 column (25 cm 
x 9 mm, 5 mm) using a Shimadzu SPD 10A HPLC system. Elution profiles were 
monitored by UV absorbance at 232 nm and fluorescent detection using a 
Shimadzu RF10AXL spectrofluorometer. Buffer A was 150 mM NaOH and 
Buffer B was 150 mM NaOH, 2 M NaCl. Elution profiles were monitored by UV 
absorbance at 232 nm and fluorescent detection at lex = 488 nm lem = 520 nm. 
Samples were injected and the flow held at 2 ml min-1 in buffer A until all 
remaining free tag had been eluted. Fluorescently labelled disaccharides were 
then eluted using a linear gradient of 0-50% buffer B over 50 min at 1 ml min-1. 
The column was then washed with a 10 min elution in 300 mM NaOH, 2 M 
NaCl, before returning to 150 mM NaOH. 
 
 
 
 
 
 
 
